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Summary (English) 
 
Metastasis is the main cause of cancer-related death. To metastasize and form new foci, tumor 
cells have to enter the bloodstream, escape from the immune system and extravasate through 
the vascular endothelium. Tumor cell extravasation is supported by the formation of tumor 
emboli which are aggregates of tumor cells with platelets and leukocytes. These aggregates 
protect tumor cells from clearance by the immune system, thereby enhancing metastasis. 
Platelet adherence on tumor cells is mediated by P-selectin and platelets contribute 
considerably to metastasis. Although leukocytes have been observed in interaction with tumor 
cells, their role remained to be elucidated. Attenuation of metastasis was observed in L-
selectin deficient mice, implicating leukocytes as potential facilitators. In this project, we 
aimed to define the nature and function of leukocytes in the tumor cell emboli as possible 
mediators of metastasis based on the observation that leukocytes were associated with tumor 
cells in lung tissues. We established a transmigration assay of tumor cells in presence of 
leukocytes in vitro and showed that depending on L-selectin expression, both granulocytes 
and monocytes were contributing to tumor cell transmigration. This enhanced migration was 
associated with an increased permeability of the vascular endothelium. The function of 
granulocytes and monocytes was then investigated in vivo. Depletion of monocytes led to a 
strong attenuation of metastasis, implicating monocytes as an important contributor of 
metastasis. Taken together these data provide evidence for an involvement of leukocytes in 
metastasis and indicate that L-selectin mediates this process. 
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Zusammenfassung (Deutsch) 
 
Die meisten Krebspatienten sterben aufgrund der Metastasierung von Tumorzellen. Um zu 
metastasieren und neue Metastasen zu bilden, müssen Tumorzellen in die Blutbahn eintreten, 
die Immunabwehr umgehen und durch die Blutgefäßwand wandern. Die Diapedese von 
Tumorzellen ist durch die Bildung von sogenannten Tumorzellemboli begünstigt, welche aus 
Aggregaten von Plättchen und Leukozyten um die Tumorzellen bestehen. Diese Aggregate 
helfen den Tumozellen dem angeborenen Immunsystem zu entgehen und einen Metastase zu 
generieren. Plättchen interagieren mit Tumorzellen über P-Selektin und tragen zur 
Metastasierung bei. Obwohl Leukozyten mit Tumorzellen interagieren, bleibt Ihre Rolle 
unklar. Die Reduktion der Metastasierung in L-Selektin defizienten Mäusen deutet auf 
Leukozyten als potentielle Vermittler hin. Das Ziel dieses Projektes war es, die Natur und die 
Funktion der Leukozyten in Tumorzellemboli zu bestimmen und ihre Beteiligung an der 
Metastasierung nachzuweisen. Leukozyten sind mit Tumorzellen in Lungengewebe assoziiert. 
Wir untersuchten die in vitro Funktion der Leukozyten und konnten nachweisen, dass in 
Abhängigkeit von der L-Selektin Expression sowohl Granulozyten, als auch Monozyten zur 
Tumorzelltransmigration beitragen. Die verstärkte Migration ist mit einer erhöhten 
Blutgefässdurchlässigkeit korreliert. Die Granulozyten- und Monozytenfunktionen wurden 
dann auch in vivo untersucht. Eine Depletion der Monozyten führt zu einer verminderten 
Metastasierung, was diesen einen massgeblichen Beitrag zur Metastasenbildung bescheinigt. 
Diese Resultate zeigen dass durch L-Selektin und demnach durch Leukozyten Metastasierung 
begünstigt wird. 
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Section I: INTRODUCTION 
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1 Cancer, an inflammatory disease 
1.1 Epithelial cancer / carcinoma 
The majority of human tumors arise from epithelial tissues. These tumors, called carcinomas 
are responsible for more than 80 % of cancer-related deaths in the Western World (Weinberg, 
2007). The other 20 % are due to sarcomas, myelomas, leukemias and lymphomas. 
Carcinomas are classified into two major categories, reflecting the two major biological 
functions associated with epithelia. Tumors that arise from epithelial cells forming protective 
cell layers are called squamous cell carcinomas (e.g., cancer of the skin or esophagus). 
Carcinomas originating from epithelial cells of glandular tissue (like mucous glands from the 
lungs and the stomach) are called adenocarcinomas. 
Migration of cancer cells from the original tumor site through the blood and lymph vessel to 
produce cancers in other tissues is called metastasis and is the leading cause of death due to 
cancer. An earlier detection of cancer could reduce the death by metastasis. 
 
Hanahan and Weinberg proposed six physiological changes that most if not all cancers 
acquire during their development. These changes are 1) the insensitivity to anti-growth 
signals, 2) the self-sufficiency of growth signals, 3) the evasion from apoptosis 4) the limitless 
potential to replicate, 5) the sustained angiogenesis, and 6) tissue invasion and metastasis 
(Hanahan and Weinberg, 2000). Tumor progression is driven by a sequence of alterations 
affecting cell proliferation, adhesion, survival, invasion and migration, all processes being 
associated with the acquisition of a malignant phenotype. The aim of this project was to study 
mechanisms leading to the initiation of metastasis. 
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1.2 Chronic inflammation associated with cancer 
In 1863, Rudolf Virchow suggested a connection between cancer and chronic inflammation 
after the observation of leukocytes in neoplastic tissues (Balkwill and Mantovani, 2001). 
Tumors are considered as `wounds’ that do not heal (Dvorak, 1986). Thus, inflammation and 
accompanying inflammatory cells and cytokines are commonly involved in tumor promotion 
and progression. 
Chronic inflammation can lead to human carcinomas (Table 1). For example, aetiologic 
agents, like chronic airway irritation and tobacco smoke are promoters of lung cancer. 
Infectious agents, like hepatitis B and C viruses and accompanying inflammation of the liver 
are associated with hepatocellular carcinomas, whereas infections with Helicobacter pylori 
are associated with most gastric cancers. Underlying infections and inflammation are linked 
to 15-20 % of all cancer deaths (Kuperwasser et al., 2004).  
 
Pathologic condition  Associated neoplasm  Aetiologic agent 
bronchitis  lung carcinoma  silica, smoking 
      (nitrosamines, peroxides) 
inflammatory bowel disease  colorectal carcinoma    
Crohn's disease       
chronic ulcerative colitis       
chronic pancreatitis  pancreatic carcinoma  alcoholism, 
hereditary pancreatitis     mutation in trypsinogen gene 
skin inflammation  melanoma  ultraviolet light 
cancer associated with infectious agents 
gastritis, ulcers  gastric adenocarcinoma  Helicobacter pylori 
hepatitis  hepatocellular carcinoma  hepatitis B and / or C virus 
mononucleosis  B‐cell non‐Hodgkin's lymphoma  Epstein‐Barr virus 
   Burkitts lymphoma    
AIDS  non‐Hodgkin's lymphoma  human immunodeficiency virus 
   squamous cell carcinoma  human herpes virus type 8 
   Kaposi's sarcoma    
 
Table 1: Chronic inflammatory conditions associated with neoplasms. Figure adapted from (Coussens and 
Werb, 2002). 
 
One good example of inflammation-associated cancer is the inflammatory bowel disease 
(IBD) –associated cancer. IBD makes reference to two diseases due to an altered host 
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response to normal intestinal bacterial flora: ulcerative colitis and colonic Crohn’s disease 
which are both associated with risk for colorectal cancer (Rhodes and Campbell, 2002). There 
is a strong correlation between the duration and extent of inflammation of the mucosa and the 
cancer risk. The gut is the largest lymphoid organ in the body and in germ-free animals the 
colon inflammatory cells were greatly reduced indicating that a ‘normal’ colon can be seen as 
being in a perpetual state of inflammation (Figure 1). 
 
As a consequence of this observation, inhibition of inflammation could then reduce the 
incidence of sporadic cancer. It was indeed shown that daily ingestion of aspirin reduces by 
half the risk of sporadic colon cancer (Dubois, 2000). Later, clinical studies report that the 
inhibition of chronic inflammation by nonsteroidal anti-inflammatory drugs (NSAIDs), 
particularly inhibitors of inducible cyclo-oxygenase COX-2, were promising as anticancer 
drugs (Pham-Nguyen et al., 1999). COX-2 has indeed a favorable effect to cancer 
development by inhibiting apoptosis and promoting angiogenesis (Rhodes and Campbell, 
2002). 
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Figure 1: Mechanisms for colon cancer development as a consequence of inflammation. Colon cancer is 
associated with underlying inflammation like IBDs. Cytokines released by this inflammatory environment lead 
to an increase in mucosal proliferation and to a reduction in mucosal apoptosis thereby increasing the chance of 
cancer development. Figure adapted from (Rhodes and Campbell, 2002). 
 
Cytokines mediate underlying inflammations and attract immune cells on the site of primary 
tumor. Tumor cells interact with these inflammatory cells to support their growth and 
development. The resulting dialogue leads to an enhanced tumor progression.  
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1.3 Cytokines in tumor progression 
During chronic inflammation, tissue damage or chronic infection, both tumor cells and tumor-
associated leukocytes and platelets produce inflammatory cytokines (like tumor necrosis 
factor TNF, IL-1 and -6) and chemokines (like IL-8). These cytokines and chemokines may 
facilitate cancer progression as illustrated by the case of the cytokine TNF. It selectively 
destroys blood vessels at high doses, whereas when it is chronically produced, it may 
contribute to tissue remodeling and tumor growth (Figure 2). For example, mice depleted for 
TNF were resistant to skin carcinogenesis (Moore et al., 1999) and in a model of ovarian 
cancer, TNF-α, constitutively expressed on the malignant epithelium, promoted cancer growth 
and spread (Kulbe et al., 2007). In clinic, TNF-α antagonists give encouraging results in 
patients with advanced myeloma (Singhal et al., 1999). 
 
 
 
Figure 2: The knowledge of the cytokine balance is crucial to determine cancer progression. Cytokines can have 
a pro- or an anti-inflammatory effect, leading respectively to two opposite effects: rapid tumor growth or tumor 
regression. Figure reprinted from (Coussens and Werb, 2002). 
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Chemokines are chemotactic cytokines, that can be expressed by carcinomas and which are 
able to attract leukocytes to inflammation sites (Balkwill, 2004; Kakinuma and Hwang, 
2006). Immune cells, endothelial cells and tumor cells express chemokine receptors and are 
able to respond to chemokine gradients, like neutrophils, that migrate in the presence of 
CXCL8 (IL-8). Chemokines contribute also to tumor cell growth, as illustrated by IL-8, that 
acts as autocrine growth factor for melanoma, liver, pancreatic and colon cancer cells 
(Schadendorf et al., 1995). Many chemokine receptors are involved in metastasis and CXCR4 
is the most common chemokine receptor overexpressed in human cancers (Table 2). It is 
implicated in lung metastasis; indeed, mice injection of CXCR4-expressing cancer cells leads 
to metastasis to lungs whereas injection of tumor cells treated with a neutralizing antibody 
against CXCR4 leads to an attenuation of metastasis (Muller et al., 2001). CXCR4 can be 
activated by its ligand CXCL12 which has been shown to increase metastatic properties, 
growth and survival of tumor cells (Scotton et al., 2002).  
 
Chemokine receptor Site of metastasis Cancer cell type Involvement 
CXCR4 lung   migration 
  bone 23 different cancers* growth/ survival 
  lymph node   angiogenesis 
CCR4 skin Sezary cells 
(leukemic CTCL) 
migration 
CCR7 lymph node melanoma migration 
  gastric, esophageal   
    CLL lung   
CCR9 small intestine melanoma, prostate migration 
CCR10 skin melanoma migration 
    CTCL growth/survival 
 
Table 2: Chemokine Receptors in Cancer Metastasis. Chemokine receptors overexpressed in human cancers are 
implicated in tumor progression and metastasis. Table reprinted from (Kakinuma and Hwang, 2006). 
* Breast cancer, ovarian cancer, glioma, pancreatic cancer, prostate cancer, acute myeloid leukemia, B-chronic 
lymphocytic leukemia, B-lineage acute lymphocytic leukemia, non-Hodgkin’s lymphoma, intraocular 
lymphoma, follicular center lymphoma, chronic myelogenous leukemia, multiple myeloma, thyroid cancer, 
colorectal cancer, squamous cell cancer, neuroblastoma, renal cancer, astrocytoma, rhabdomyosarcoma, small-
cell lung cancer, melanoma, and cervical cancer. Abbreviations: CTCL: Cutaneous T cell lymphoma; CLL: 
chronic lymphocytic leukemia.  
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1.4 Interactions  of  primary  tumors  with  their 
microenvironment 
 
The developing tumors have a complex relationship with the cells from their 
microenvironment (de Visser et al., 2006). In the early growth of tumors, cancer cells form a 
neoplastic lesion that is embedded in the epithelium, separated from the surrounding tissue 
and contained within the boundary of a basement membrane (Hanahan and Weinberg, 2000). 
This is called the carcinoma in situ (CIS). The basement membrane, the immune cells, the 
capillaries, the fibroblasts, and extracellular matrix (ECM) surrounding the cancer cells 
constitute the tumor stroma (Ronnov-Jessen et al., 1996). This stroma is comparable to that 
observed in wound healing and is called reactive stroma. There is evidence that the reactive 
stroma and CIS can communicate with each other through the basement membrane barrier 
(Ronnov-Jessen et al., 1996). It is not yet fully understood how CIS becomes an invasive 
carcinoma by degrading the basement membrane (Kalluri, 2003). Reactive stroma is 
associated with an increased number of fibroblasts, enhanced capillary density, and type-I-
collagen and fibrin deposition and gives oncogenic signals that facilitate tumorigenesis 
(Dolberg et al., 1985). Vascular endothelial growth factor (VEGF) plays a role in the 
emergence of the reactive stroma (Brown et al., 1999).VEGF is released by cancer cells, 
fibroblasts and inflammatory cells leading to the recruitment of blood vessels by tumor cells, 
a process called angiogenesis. It has been shown in a mouse model, that inflammatory cells 
are then recruited and release MMP-9 that cleaves ECM components and liberates latent 
inactive VEGF from its sequestered state (Nozawa et al., 2006). VEGF acts on endothelial 
cells causing them to proliferate and invade hypoxic tumor tissues expressing hypoxia-
inducible factor 1 (HIF-1) in order to supply them with blood vessels. The resulting 
enhancement in microvascular permeability of the tumor-associated capillaries and venules 
and extravasation of plasma proteins such as fibrin attract an influx of fibroblasts, 
inflammatory cells and endothelial cells (Dvorak et al., 1991). During cancer progression, the 
tumor cells invade the reactive stroma and come into direct contact with fibroblasts, 
inflammatory cells and newly formed capillaries (Dvorak, 1986). Carcinoma-associated 
fibroblasts (CAFs) are playing a role in the initiation and progression of cancer, as well as in 
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metastasis (Kalluri and Zeisberg, 2006). The figure 3 shows the microenvironment of tumor 
cells and potential new therapeutics directed towards deprivation of tumor cells stromal 
support. 
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Figure 3: Heterotypic interactions as targets for therapeutic intervention. Cancer cells are dependent on the 
nearby environment for a variety of cell physiologic supports. This dependence on heterotypic interactions has 
inspired a new type of cancer therapy. Instead of focusing on intracellular defects within cancer cells, this new 
type of therapy is directed towards depriving tumor cells of their essential stromal support. This scheme indicates 
some of the anti-tumor therapies that are being developed or under consideration. Figure reprinted from 
(Weinberg, 2007). 
 
The inflammatory microenvironment of tumor cells is mostly constituted of leukocytes. A 
variety of leukocyte populations have been involved in the promotion of tumor growth and 
metastasis. These populations include macrophages (the TAM, Tumor-Associated-
Macrophages), granulocytes and myeloid suppressor cells. Dendritic cells and lymphocytes 
are also present in tumor cell infiltrates (Negus et al., 1997). For example, in a mouse model 
of epithelial carcinogenesis, B lymphocytes were required for establishing chronic 
inflammatory states that promote de novo carcinogenesis (de Visser et al., 2005). In colorectal 
cancer, the tumor infiltration by dendritic cells and their localization was correlated with a bad 
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prognosis for the patient (Sandel et al., 2005). MMP-9 expressing neutrophils were shown to 
play an important role in the early stages of carcinogenesis in activating angiogenesis 
(Nozawa et al., 2006). 
 
Tumor-Associated Macrophages (TAM) 
The Tumor-associated Macrophages (TAM) represent the major population in tumor 
infiltrates and have been shown to be implicated in many steps of tumor progression. TAM 
are the most abundant cells to be recruited by tumor cells and attracted on primary tumor sites 
by cytokines. They accumulate in hypoxic areas of tumors due to HIF-1 dependent 
upregulation of the chemokine receptor CXCR4 (Schioppa et al., 2003). They are obligatory 
partners for tumor metastasis and well studied (Pollard, 2004; Wyckoff et al., 2007). The 
association of chronic inflammation with cancer together with positive results obtained with 
anti-inflammatory drugs support the role of TAM in cancer (Balkwill et al., 2005). In 
addition, it has been shown that a high density of TAM is correlated with a poor prognosis for 
cancer patients (Bingle et al., 2002; Lin et al., 2002). TAM have a dual role (Mantovani et al., 
1992). On the one hand, they can eliminate tumor cells; on the other hand, they can promote 
tumor progression by producing growth factors for tumor cells or even proteases that would 
help to degrade the ECM. This last property was illustrated by a study showing that TAM can 
contribute to skin carcinogenesis by producing MMP-9 (Coussens et al., 2000). The 
overexpression of colony-stimulating factor-1 (CSF-1) recruiting macrophages in a mouse 
model of breast cancer leads to tumor progression and metastasis (Lin et al., 2001), whereas 
the removal of macrophages in the same model by knocking-down the gene coding for CSF-1 
dramatically reduced the rate of metastasis. Moreover, macrophages were shown to promote 
tumor angiogenesis. Indeed, angiogenic switch and the progression to malignancy were 
shown to be regulated by infiltrated macrophages in a mouse mammary tumor (Lin et al., 
2006). Depletion of TAM by clodronate-liposomes leads to a reduction of tumor growth in 
murine and human models most probably due to the inhibition of angiogenesis (Zeisberger et 
al., 2006). 
Macrophages are clearly associated with tumor development; however their precise function 
still remains to be defined. How do macrophages help tumor cells to progress at distant sites? 
What are the underlying mechanisms involved in this process? 
 
The molecular mechanisms linking inflammation and development of carcinomas are being 
intensively studied (de Visser et al., 2006; Karin, 2006; Luo et al., 2007). The role of NFκB 
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and its activating IκB kinases were shown to be crucial in the regulation of cell survival and 
production of pro-inflammatory cytokines. Macrophages enhanced cancer metastasis in the 
mouse model of prostate cancer by secreting the proinflammatory cytokine receptor activator 
of NFκB ligand RANKL (Luo et al., 2007). In these primary prostate cancers, RANKL has 
been shown to be expressed by infiltrating T lymphocytes and macrophages. In addition, it 
was shown that prostate cancer cells produce higher amount of the chemokine MCP-1 
(Monocyte Chemotactic Protein-1), chemokine recruiting leukocytes during inflammation, 
and that MCP-1 in addition to IL-8 mediates tumor-induced osteoclast activities important for 
bone metastasis (Lu et al., 2007). 
 
Mice bearing transplantable tumors, but also mice having cancer as a consequence of 
chemical carcinogenesis undergo a progressive accumulation of myeloid suppressor cells 
(MSCs) in the spleen and blood. This increase can be taken as an indirect measure of tumor 
dissemination (Melani et al., 2003). These cells share the CD11b and the Gr-1 markers and 
are a heterogeneous population, enclosing granulocytes, monocytes and varying numbers of 
immature cells of the myelomonocytic lineage (Serafini et al., 2004). In the 1980’s, a first 
evidence was found for a correlation between myeloid cell accumulation and immune 
suppression (Maier et al., 1989; Subiza et al., 1989). In a mouse adenocarcinoma model, it 
was reported that TAM can induce apoptosis in activated T cells by a mechanism requiring 
cell contact, TNF-α, and NO production (Saio et al., 2001; Serafini et al., 2004).  
 
Accumulating evidences strongly support the decisive role of macrophages associated with 
tumor cells in the contribution to tumorigenesis. Growth factors produced by macrophages 
support the tumor cell microenvironment and stimulate angiogenesis. 
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2 Cell‐cell interactions during metastasis 
2.1 Metastasis 
Metastasis is defined as spread of primary tumors to a distant organ. These distant settlements 
of tumor cells are the cause of 90 % of human cancer death (Sporn, 1996). The spread of 
metastases can occur via the blood or lymphatic vessels or through both routes. 
In 1889, Stephen Paget has proposed that metastasis is not random but a cross-talk between 
the tumor cells as ‘seeds’ and a specific organ microenvironment as ‘the soil’ (Paget, 1889). 
This ‘seed an soil’ theory suggested that the destiny of tumor cells was not by chance but that 
tumor cells form metastases only in organs where the ‘soil’ is favorable (Fidler, 2003). In 
1929, James Ewing challenged this theory by the affirmation that metastasis occurs only by 
mechanical factors resulting from the anatomical structure of the vasculature. But Paget’s 
theory is nowadays considered to be the closest to the reality (Liotta and Kohn, 2001). 
Metastasis is a very inefficient mechanism, because most of the tumor cells that enter the 
bloodstream are rapidly eliminated (Fidler, 2003). Less than 0.05 % of circulating tumor cells 
are successful in initiation of metastatic colonies. Metastasis formation is a highly selective 
process, which contradicts a widely accepted belief that metastasis represents the ultimate 
expression of cellular anarchy. It has been shown that primary tumors influence the 
environment in the lungs before metastasis. Tumors secrete VEGF-A, TGFβ and TNFα, 
which induce expression of chemokines by myeloid cells and endothelial cells within the 
lungs before metastasis and this chemokine-activated premetastatic niche supports adhesion 
and invasion of malignant cells (Hiratsuka et al., 2002; Kaplan et al., 2005).  
 
In the present work we focused on the mechanism of hematogenous metastasis. The tumor 
cells first acquire the capacity to degrade and breach the basement membrane and invade 
blood vessels in a process called intravasation (Weinberg, 2007). They have then to survive in 
the circulation which is a hostile environment for metastasizing cancer cells due to the 
presence of innate immune cells. Indeed, they have to escape the clearance by immune cells, 
they are threatened by dying from anoikis and they have to survive the hydrodynamic shear 
forces in the circulation. The survival of these cells has been shown to be enhanced by 
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aggregation of platelets around them (Nieswandt et al., 1999; Palumbo et al., 2005). Tumor 
cell interaction with platelets and leukocytes, leading to the formation of a microembolus 
facilitates their arrest in the vasculature (Honn et al., 1992b; Karpatkin et al., 1988; Kim et al., 
1998). The cells finally arrest in a new organ and extravasate from the circulation into the 
surrounding tissue (Figure 4).  
 
 
Figure 4: Metastasis is a multi-step process. Figure reprinted from (Fuster and Esko, 2005). 
 
Capillaries have diameter of 3-8 μm allowing the passage of red blood cells which are about 7 
μm in diameter and highly deformable but not allowing the passage of tumor cells which are 
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much bigger (20 μm) and not so deformable (Chambers et al., 2002). The coating of the 
tumor cells by platelets further increases their diameter, causing them to be trapped also in 
larger vessels. Structural and molecular basis for the arrest of such emboli in the vasculature 
and for the formation of a new metastatic site remains to be fully elucidated. For example, 
pulmonary arrest does not occur merely due to size restriction of the capillaries but the early 
arrest of tumor cells in the pulmonary vasculature can be mediated through interaction of 
α3β1 integrin with laminin-5 in exposed basement membrane. (Wang et al., 2004). The role 
of platelets and leukocytes in tumor cell entrapment in the vasculature has been extensively 
studied (Borsig et al., 2002; Honn et al., 1992a; Karpatkin et al., 1988). Platelets, leukocytes 
and tumor cells form tumor cell emboli in the vasculature leading to an enhanced tumor cell 
progression. The platelet aggregation around tumor cells protects the tumor cells from the 
native immune system and facilitates the arrest and extravasation of tumor cells at new 
metastatic sites (Borsig et al., 2002; Kim et al., 1998). 
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2.2 Alteration  in  tumor  cell  surface  glycosylation  and 
tumor progression 
 
Alterations associated with malignancy 
 
Many alterations are associated with carcinoma malignancy. Tumor progression involves 
alterations in both intracellular and extracellular signaling. In order to metastasize, cells need 
to be able to detach from other cells and from the substrate by alteration of cell-adhesion 
molecules, like cadherin, and in cell surface glycosylation. Tumor cells need then to degrade 
the extracellular matrix by releasing matrix metalloproteinases, like MMP-9 and to migrate 
through host ECM and basement membranes. Further progression needs recruitment of an 
endothelial-lined neovascular network from endothelial cells for angiogenesis, to acquire cell-
surface characteristics that promote adhesion with platelets, leukocytes and endothelial cells 
and to escape innate immunity. Finally, metastases are formed from cells that survive. 
 
O-Glycan alteration during tumor progression 
 
Several glycans on the tumor surface have now been identified as mediating key events 
during the various steps of tumor progression (Fuster and Esko, 2005). During the process of 
tumorigenesis, the cells undergo a transformation called epithelial-mesenchymal transition 
(EMT). During EMT, epithelial cells adopt a migratory phenotype and this transition is 
recognized as a pathological process contributing to cancer progression (Arias, 2001). During 
this process, epithelial cells lose their polarity, and mucins expressed all over the cell block 
cell-cell and cell-substratum adhesion through a mechanism of repulsion (Figure 5). 
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Figure 5: Tumorigenesis and loss of apical expression of mucins. During EMT, epithelial cells lose their 
polarity, and mucins are aberrantly expressed, blocking cell-cell and cell-substratum adhesion. Figure reprinted 
from (Hollingsworth and Swanson, 2004). 
 
O-linked glycans are extremely diverse in both structure and function and are built on protein-
glycan linkages, in which sugar structures like GalNAc, fucose, mannose or galactose can be 
attached to seronine, threonine or hydroxylysine residues. Mainly two groups of 
glycoproteins, mucins and proteoglycans are dominated by the large number of O-linked 
glycans they bear. During EMT, epithelial cells lose their polarity and do not express mucins 
on their apical surface anymore (Figure 5). Mucins, highly O-glycosylated proteins have an 
important role in maintaining homeostasis for epithelial cells living in variable environment. 
In comparison with O-glycans from normal mucin, O-glycans from cancerous mucins can be 
highly sialylated and less sulphated (Brockhausen, 2006). The metastatic potential of tumor 
cells has been correlated with increasing sialylation of cell-surface glycoproteins (Taylor and 
Drickamer, 2006). The O-glycans can also be truncated and contain the Tn (GalNAc-) and T 
(Galβ1-3GalNAc-) antigens (Table 3). 
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O‐glycan Increased  Structure  Increase  / 
decrease  in 
cancer* 
Tn antigen  . GalNAcα‐Ser/Thr  ↑ 
STn antigen  . Sialylα2‐6GalNAcα‐Ser/Thr  ↑ 
Core 1, antigen  . Galβ1‐3GalNAcα‐Ser/Thr  ↑ 
Sialyl‐T antigens  . Sialylα2‐3Galβ1‐3GalNAcα‐Ser/Thr  ↑ 
   . Sialylα2‐6(Galβ1‐3)GalNAcα‐Ser/Thr  ↑  
Core 2  . GlcNAcβ1‐6(Galβ1‐3)GalNAcα‐Ser/Thr  ↑↓ 
Core 3  . GlcNAcβ1‐3GalNAcα‐Ser/Thr  ↓ 
Core 4  . GlcNAcβ1‐6(GlcNAcβ1‐3)GalNAcα‐Ser/Thr  ↓ 
Type 1 chain  . [GlcNAcβ1‐3 Galβ1‐3]n  ↓ 
Type 2 chain  . [GlcNAcβ1‐3 Galβ1‐4]n     
   . Poly‐N‐acetylactosamines  ↑ 
Sialyl‐Lewisa  . Sialylα2‐3Galβ1‐3 (Fucα1‐4)GlcNAcβ1‐3Gal‐  ↑ 
SLex  . Sialylα2‐3Galβ1‐4 (Fucα1‐3)GlcNAcβ1‐3Gal‐  ↑ 
Sialyl‐dimeric Lewisx  . Sialylα2‐3Galβ1‐4 (Fucα1‐3)GlcNAcβ1‐3   ↑ 
                        Galβ1‐4 (Fucα1‐3)GlcNAcβ1‐3Gal‐    
 
Table 3: Mucin-type O-glycans and alterations in cancer.*The symbol ↑ denotes an increase in cancer, whereas 
the symbol ↓ denotes a decrease. Table adapted from (Brockhausen, 2006). 
 
These alterations of glycosylation with aberrant terminal sugar structures of O-glycan chains, 
such as Lewis antigens and sialic acids, play an important role in the biology of cancer. 
Indeed, the interactions between cancer cells and their microenvironment can be mediated 
through sugar binding molecules, like lectins. The number of sialyl-Lewisx (SLex) epitope, 
tetrasaccharide, characterized by the presence of terminal fucose and sialic acid residues, is 
correlated with a poor survival of patients with colon cancer (Nakamori et al., 1993) (Figure 
6). 
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Figure 6 : The number of sialyl-Lewisx (SLex) epitope is correlated with a poor survival of patients with colon 
cancer. Figure reprinted from (Nakamori et al., 1993). 
 
Compared with primary tumors, metastatic cancer cells have often increased amount of sLex 
and sLea, as well as sialyl-dimeric Lewisx (Ito et al., 1997) (Figure 7-A). These structures are 
normally involved in the attachment of leukocytes to endothelium via selectin molecules, 
during an inflammatory process, for example. Overexpression of glycosylated structures is 
not the only alteration associated with carcinoma malignancy. Some glycans can be truncated, 
like the sialyl-Tn epitope / antigen, which is a truncated O-linked glycans and exposed at high 
levels on a variety of carcinomas (Figure 7-B). O-glycans can be truncated in vitro by 
inhibiting glycosyltransferases. 
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Figure 7: Glycosylated structures involved in carcinoma malignancy: A Sialyl Lewisx and a. Expression of these 
structures by cancer cells is linked with carcinoma malignancy. Figure reprinted from (Lowe, 2003). B Tn and T 
antigen. Incomplete glycosylation in the O-linked pathway results in expression of the Tn antigen, the sialylated 
Tn antigen (a "dead-end" structure), or the T antigen (Thomsen-Friedenreich antigen, or unmodified Core 1 
structure). Multiple copies of these structures may occur in a closely spaced array on the polypeptide. Figure 
reprinted from (Varki et al., 1999). 
 
O-linked oligosaccharide synthesis was inhibited by benzyl-alpha-N-acetylgalactosamine -
benzyl-alpha-GalNAc- (Kuan et al., 1989). Benzyl-alpha-GalNAc is a substrate decoy 
molecule for GalNAc transferase and can therefore reduce the glycosylation of cell-surface 
glycoproteins. The accumulation of O-linked αGal-NAc at the surface of the cells, resulting 
from this blocking can be quantified through increased reactivity with FITC-labeled Helix 
pomatia lectin. The use of this inhibitor on colon cancer cells reduces the mucin-type O-
glycans as well as their attachment to E-selectin and endothelial cells (Kojima et al., 1992). In 
addition, tumor cell treatment with an acetylated disaccharide, inhibitor of the biosynthesis of 
sLex in a model of spontaneous metastasis in mice attenuates metastasis in vivo (Brown et al., 
2006), suggesting that alteration of O-glycosylation has a direct effect on invasion and 
metastasis. 
A study of the binding of colon cancer cells with purified selectins showed that L- and P-
selectin interact with mucin-type ligands on colon cancer cells whereas E-selectin can 
recognize both mucin and non-mucin ligands (Mannori et al., 1995). This finding correlates 
with the hypothesis that colon cancer cells adhere to activated endothelium (E-selectin 
dependent), platelets (P-selectin dependent) and leukocytes (L-selectin dependent). 
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Furthermore clustered presentation of sLex on tumor cell mucins is suggested to facilitate 
metastasis through binding to selectin on platelets, leukocytes and endothelial cells (Kim et 
al., 1999). 
Changes in glycosylation are due to an up- or down-regulation of the glycosyltransferases or 
their mislocalization in the secretory pathway of tumor cells. Many tumor cells have altered 
mRNA levels and activities of glycosyltransferases. In human colon adenocarcinoma of high 
grade, the type 2 chains, precursor for the sLex antigen, are produced and the activity of β4-
Gal-transferase involved in their synthesis is upregulated (Table 3). Increased activities of α-
2,3-sialyltransferases leading to an increased amount of sLex in colon carcinomas have also 
been detected (Majuri et al., 1995). 
Carcinomas commonly express O-linked glycans that present ligands for selectins, promoting 
tumor cells interaction with platelets, leukocytes and endothelial cells. These interactions are 
suggested to facilitate haematogenous metastasis of tumor cells. 
 
Tumor-associated antigens 
 
Tumor-associated antigens (TAAs) on several mucins have an oligosaccharide structure and 
some correspond to blood-group antigens (Piller et al., 1980). Carcinoma mucins are secreted 
in the circulation and can be used as markers. Serological markers like CA125, CA19-9 and 
CA15-3 are mucin glycoconjugates commonly overexpressed by ovarian, pancreatic and 
breast adenocarcinomas, respectively. Serum levels of these TAAs correlate with tumor 
burden and poor prognosis. Antibodies against the TAAs are used as diagnostic tools in serum 
assays. For instance, the mAb CA19-9, recognizing sLea on pancreatic carcinoma mucins is 
used for the detection of colorectal and pancreatic adenocarcinoma (Hayashi et al., 2004). 
Oncofetal antigens like carcinoembryonic antigen (CEA) and the breast cancer MUC-1 are 
overexpressed in tumors but can be expressed in other tissues as well. Since these antigens are 
also found in fetal tissues, it is not so easy to use them as therapeutic targets. Indeed, 
peripheral tolerance to these antigens can exist and a vaccination could lead to autoimmune 
reactions. 
 
N-glycans and tumor progression 
 
Tumor progression associated with changes in glycosylation is not only due to changes in O-
glycans; it has been shown in a model of breast cancer, that tumor progression is associated 
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with increased β-1,6-GlcNAc-branching, a regulatory step in expression of polylactosamine 
and extended-chain Lewis antigens. This increased sialylation and increased branching of 
complex N-linked oligosaccharides in metastatic cells results from an increased activity of 
GlcNAc-transferase V (GnTV). For example, the presence of complex β-1,6-branched N-
glycans on tumor-cell E-cadherin -an adhesion molecule that normally mediates cell 
aggregation - reduces tumor cell–cell adhesion. Therefore, increased expression of this 
enzyme promotes cell detachment and invasion (Dennis et al., 2002; Fuster and Esko, 2005; 
Yoshimura et al., 1996). Interestingly, E-cadherin is often downregulated by invasive cancers 
(Hirohashi and Kanai, 2003). 
In addition, increased β-1,6-branching on the β1 subunit of tumor α5 β1 integrins, disrupts the 
ability of integrins to cluster on the tumor-cell membrane (Guo et al., 2002) This altered 
integrin clustering reduces the formation of tumor-cell focal adhesions, and increases tumor 
motility through the ECM as well as invasion across basement membranes.  
Treatment of the cells with Swainsonine and other inhibitors of N-linked oligosaccharide 
synthesis, blocks tumor cell invasion in vitro and reduces tumor growth in vivo (Kim and 
Varki, 1997; Korczak et al., 1994). 
Tumors aberrantly express various glycans that regulate many different aspects of tumor 
progression. Investigating the role of O-linked glycans in tumor progression is one of the aims 
of our study. Tumor mucins present ligands for various cell adhesion molecules, such as 
selectins, that can mediate the interactions with platelets, leukocytes and endothelial cells. 
These interactions may facilitate haematogenous metastasis of tumor cells. 
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2.3 Selectins and their physiological functions 
Lectins are proteins or glycoproteins which recognize carbohydrate structures. They have 
diverse functions, being implicated in innate immunity (for example the mannose-binding 
protein MBP), in antigen presentation (C-type lectin), in adhesion (selectins) and signaling 
events (galectins, I-type lectins like siglecs) or in T-cell apoptosis (galectin-3, -1 and -9). 
Many lectins can potentially recognize the altered glycosylation of cancer cells (Kim and 
Varki, 1997). For example, galectins (especially galectin-3) can interact with poly-N-acetyl-
lactosamines on laminin, helping invasion and could bind also polylactosamines expressed on 
cancer mucins (Inohara et al., 1996). A complement regulatory protein, the H protein and I-
type sialic acid binding proteins like CD22 are also potential helpers in the invasion 
mechanism (Kim and Varki, 1997). 
More particularly, the selectins, which have important physiological functions in cell 
adhesion mediating leukocytes rolling on endothelium in response to inflammation, have 
shown to be active players in cancer. We are studying carcinoma cells with altered 
glycosylation, expressing sialylated fucosylated mucins that can interact with platelets, 
leukocytes and endothelium via the selectin family of cell adhesion molecules.  
 
Selectin family 
 
Selectins are transmembrane C-type lectins that bind carbohydrates in a calcium dependent 
manner (Kansas, 1996). They are cell-adhesion molecules for leukocytes, playing a role in the 
homing of T- and B- cells to peripheral lymph nodes and in the rolling of leukocytes on 
endothelium for leukocytes migration to inflammation sites (Kansas, 1996; McEver, 2002).  
There are three types of selectins: L-, P- and E-selectin, that share a very similar structure; a 
carbohydrate-binding domain at the N-terminus, an EGF-like domain, various numbers of 
consensus repeats with homology to complement regulatory proteins, a transmembrane 
domain and a cytoplasmic tail involved in signaling (Figure 8).  
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Figure 8: A generic selectin molecule binding a common ligand: sLex. There are three types of selectins: L-, P- 
and E-selectin, that share a very similar structure. 
 
L-selectin is constitutively expressed on the surface of leukocytes, E-selectin on activated 
endothelium and P-selectin is rapidly exteriorized under activation of platelets or 
endothelium. L-selectin mediates the binding of leukocytes to endothelial cells in the lymph 
nodes. P- and E-selectins help the migration of the neutrophils into sites of inflammation. 
During inflammation, endothelial cells are activated and express P-selectin stored in Weibel-
Palade bodies (Dole et al., 2005) to their cell surface thereby recruiting circulating 
neutrophils. L-selectin causes the attachment of the attracted leukocytes to the endothelium.  
L-selectin ligands on high endothelial venules (HEV) are sialomucins like GlyCAM-1 
(mouse), CD34 (mouse and human), podocalysin (human), endomucin (member of the PNAd 
complex) and MadCAM-1 (also member of the PNAd complex). These sialomucins are 
functionally redundant. This situation is totally different from the case of P-selectin, indeed its 
ligand is a single sialomucin called PSGL-1. PSGL-1 is the major leukocyte ligand for both P- 
and L-selectin (Rosen, 2004) and interestingly, PSGL-1 has been shown to mediate L-
selectin-dependent leukocytes rolling in venules (Sperandio et al., 2003). 
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The diapedesis of leukocytes in inflammation is selectin dependent 
 
Leukocytes are extravasating the circulation to enter into the parenchyma in response to 
inflammatory stimuli in a process called diapedesis. The leukocytes are able to induce the 
retraction of the endothelial cells and the process from attachment to the endothelial wall till 
the entry into the tissue takes less than a minute (Varki et al., 1999). 
This trafficking of leukocytes in postcapillary venules is a multi-step mechanism which 
involves their initial attachment to the endothelial cells, followed by rolling on the endothelial 
cell wall and finally arrest and transmigration through the endothelial cell layer (Figure 9). 
Rolling characterized by a weak adhesion is mostly selectin-mediated (L-selectin on the 
surface of the lymphocytes, E- and P-selectin on endothelial cells), whereas the strong 
adhesion and arrest is integrin-mediated (intercellular adhesion molecule (ICAM)-1 and 
vascular cell adhesion molecule (VCAM-1). The dimerization of L-selectin leads to 
stabilization of cell rolling. Indeed, glycan-lectin interactions require clustering of lectin 
domains to generate avidity between the corresponding components (Weis and Drickamer, 
1996). Inflammatory response is accompanied by an activation of the neutrophils. Briefly, 
neutrophils first roll via selectin interactions and adhere to vascular endothelium, mobilize 
secretory vesicles, enrich their surface with the β2-integrin CD11b/CD18 and shed L-selectin. 
They then extravasate and degranulate and are able in situ to eliminate microorganisms for 
example. In vitro, the stimulation with inflammatory mediators leads to a rapid release of 
secretory vesicles and granules. 
Leukocyte trafficking is affected in mice deficient in selectins (Tedder et al., 1995). The 
lymphocytes of L-selectin deficient mice were not able to bind the peripheral lymph node 
high endothelial venules -HEV- (Arbones et al., 1994). The mutant mice had a severe 
reduction of the number of lymphocytes localized to the lymph nodes. This model shows the 
important role of L-selectin in leukocyte homing to lymphoid tissues and in inflammation. 
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Figure 9: Rolling adhesion of circulating leukocytes to activated endothelium via interactions between selectins 
and their ligands. This figure shows a neutrophil expressing PSGL-1 and L-selectin and interacting with 
membrane P-selectin on endothelial cells. E-selectin may also participate in these interactions by binding to 
PSGL-1 or other ligands on these cells. Following interactions, cells are tethered and roll along the endothelium. 
Leukocyte-leukocyte interactions involving L-selectin and PSGL-1 are depicted, but L-selectin may also have 
other ligands expressed by the activated endothelium. Adherent cells become activated by regionally presented 
chemokines. The activated leukocytes express integrins that interact with Ig-like counter receptors on endothelial 
cells, strengthen the adhesion, and promote the emigration or extravasation (diapedesis) of cells into the 
underlying tissues in response to chemotactic gradients. Figure reprinted from (Varki et al., 1999). 
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2.4 Heterotypic interactions during metastasis 
Lymphatic and blood vessels are the major anatomical pathways for the dissemination of 
tumor cells. Endothelial cells and the vessels that they form ensure tumors adequate access to 
the circulation. Within the vasculature the tumor cells interact with endothelial cells, platelets 
and leukocytes. The importance of aggregation of tumor cells with cellular blood components 
for metastasis is now well established (Borsig et al., 2001b; Honn et al., 1992b; Karpatkin et 
al., 1988) 
 
2.4.1 Endothelium and metastasis 
 
Tumor cells are associated with the vasculature to access to nutrients and oxygen 
 
Endothelial cells are highly metabolically active and play a role in many physiological 
functions, like blood cell trafficking, hemostatic balance, permeability and immunity (Aird, 
2003). Tumors require access to the circulation in order to grow and survive. As early as the 
mid-1950s, pathologists realized that tumor cells preferentially grew around blood vessels. It 
has been shown that oxygen diffusion was one important explanation why tumor cells were so 
close to blood vessels. Indeed, tumor cells need effective interactions with the vasculature in 
order to acquire nutrients and to shed metabolic waste and carbon dioxide. Tissues suffering 
from hypoxia are in danger of becoming apoptotic by activation of p53-signaling. Inactivation 
of the p53-signaling system often enables tumor cells to survive beyond the small perimeter 
surrounding each capillary. The formation of blood capillaries during angiogenesis involves a 
high number of factors, like VEGF, TGF-β, basic fibroblast growth factors (bFGFs), 
interleukin-8 (IL-8), angiopoietin, angiogenin and PDGF. Moreover, mural pericytes and 
vascular smooth muscle cells help this process as well. 
 
Interactions endothelium-cancer cells in metastasis  
 
The arrest of circulating cancer cells in the vasculature is a prerequisite for their extravasation 
and growth into metastatic tumors. Mechanical factors alone are not sufficient for the ultimate 
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tumor cell arrest in target organ circulation, and specific adhesive interactions between 
metastatic cells and blood vessel endothelia are necessary for malignant cell arrest in 
microvessels. Indeed, many metastatic cells arrested in lung circulation, reside in precapillary 
arterioles of calibers far exceeding tumor cells in size (Wong et al., 2002). Adhesive factors 
and arrest specificity promote metastasis (Orr et al., 2000). The adhesion between cancer cells 
and endothelium is selectin-, integrin-, cadherin- or immunoglobulin-dependent. Indeed, in 
vitro metastatic breast and prostate carcinoma cell adhesion to microvascular endothelium is 
mediated largely by interactions between cancer-associated Thomsen-Friedenreich (TF) 
glycoantigen (Galβ1–3GalNAc) and β-galactoside-binding lectin galectin-3 (Glinsky et al., 
2001). Similarly, it has been shown that sLea and sLex, respectively on colon carcinomas and 
renal carcinomas bind the adhesion molecule E-selectin on endothelial cells (Lafrenie et al., 
1994; Steinbach et al., 1996; Ye et al., 1995). These facts demonstrate unambiguously that 
blood-borne malignant cells could be arrested in a variety of organs and tissues through 
specific adhesive interactions with vessel walls in the absence of mechanical entrapment. 
Some studies even describe a loss of endothelial barrier integrity during tumor cell 
transmigration (Heyder et al., 2002; Weis et al., 2004). Vascular permeability is characterized 
by altered cell-cell contacts and the appearance of paracellular pores between adjacent cells. 
Integrity of the endothelial barrier is regulated in part by opposing roles of the actin 
cytoskeleton in which cortical F-actin stabilizes cell-cell contacts, whereas intracellular stress 
fibers exert tension to induce permeability (Stockton et al., 2004). 
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2.4.2 Platelets and metastasis 
Circulating platelets contribute to haemostasis, thrombosis and inflammation. The presence of 
platelets in association with cancer has first been recognized by the surgeon Billroth in 1878, 
who described the association of cancer cells with a thrombus -plug of platelets and blood 
constituents- (Nash et al., 2002). In this context, an artificial decrease in platelet count leads 
to an attenuation of metastasis due to an enhanced clearance of tumor cells (Gasic, 1984). 
Thrombin is a well-known platelet activator and can be derived from tumor cells. The primary 
role of thrombin is the conversion of fibrinogen to fibrin, the building block of a hemostatic 
plug. When platelets are activated by thrombin, there is a rapid signal transduction cascade 
resulting in massive influx of Ca2+ into the platelets cytosol. This leads to a cross-linking of 
the actin filaments of the platelet that becomes activated and extend lamellipodia and 
filopodia and spread itself across the clot. Thrombin released by tumor cells leads to platelet 
activation and their adherence to tumor cells (Nierodzik and Karpatkin, 2006). Platelets that 
accumulate on tumor cells prolong tumor survival in the circulation by impeding their 
elimination by natural killer cells (NK cells) and facilitate their arrest and adhesion on 
endothelial cells, thereby helping them to extravasate and metastasize (Nieswandt et al., 1999; 
Palumbo et al., 2005). Platelets also secrete tumor cell growth and angiogenesis factors, such 
as platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) 
which leads to vascular hyperpermeability (Poggi et al., 1993). Platelet-derived 
lysophosphatidic acid (LPA) promotes tumor cell proliferation by binding the LPA1 receptor 
of breast and ovarian cancer cells (Boucharaba et al., 2004). Cancer patients have generally 
higher circulating concentrations of VEGF than healthy persons (Poon et al., 2001). Tissue 
factor, upregulated at hypoxic sites of tumor tissue leads to platelet activation as well. 
Prostacyclin, synthesized by vascular endothelial cells inhibits the action of procoagulant 
thromboxane A2 inducing platelet aggregation. The ratio prostacyclin to thomboxane A2 
concentrations is disturbed in many cancers and endothelial cells deficient in prostacyclin 
showed an increased tumor-endothelial adhesion (Honn and Tang, 1992). Inhibition of 
platelets by prostacyclin and anticoagulants are used to inhibit tumor metastasis and these 
antiplatelets agents have some anticoagulant activities. It has been shown in our group that 
heparin decreases metastasis in mice by blocking P-selectin-mediated-platelet interactions 
with tumor cell surface mucins (Borsig et al., 2001a). Low anticoagulant heparin preparations 
still inhibited metastasis efficiently, indicating that anticoagulation is not a necessary 
component for heparin attenuation of metastasis (Hostettler et al., 2007). 
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2.4.3 Leukocytes and metastasis 
Increasing evidence indicates that leukocytic infiltration can either impede tumor formation 
and growth, in a process called immunosurveillance (Dunn et al., 2004) or, alternatively, 
promote tumor phenotypes, such as angiogenesis, growth and invasion, in a process called 
immune enhancement (de Visser et al., 2006; de Visser et al., 2005). Clinical data for solid 
tumors show a correlation between high-density leukocytic infiltration into tumors and poor 
outcome for patients (Coussens and Werb, 2002). 
Neutrophils are the most abundant circulating blood leukocytes in humans. They are the first 
cells recruited to inflammation sites. They have a ‘natural’ antitumor activity and are able to 
produce many cytotoxic compounds, such as reactive oxygen species, proteases, membrane-
perforating agents and soluble factors like TNF-α, IL-1β and IFNs (Di Carlo et al., 2001). On 
the other hand, they can promote tumor progression. Indeed, neutrophils were shown to 
enhance the metastatic potential of tumor cells in many carcinoma models (Queen et al., 
2005; Tazawa et al., 2003; Welch et al., 1989). In an in vitro transendothelial model, human 
neutrophils were assisting a human breast tumor cell line to cross the endothelial barrier, 
suggesting an important role of the neutrophils in the tumor cell extravasation (Wu et al., 
2001). There are, in fact, two possible ways how neutrophils assist tumor cell migration 
through the endothelial barrier. The first possibility is that the neutrophils cause endothelial 
injury by releasing proteases and reactive oxygen species thereby causing microvascular 
permeability. This has been seen in a tumor-bearing murine model in which neutrophils-
mediated pulmonary injury facilitated metastasis in the lung (Orr and Warner, 1990). The 
other possibility is an interaction between neutrophils, highly transmigratory cells, and tumor 
cells, leading to a co-migration of the tumor cells through the endothelium. 
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2.4.4 Selectin and metastasis 
 
Selectin molecules on platelets, leukocytes, and endothelium promote metastasis 
 
Tumors carry altered cell surface glycosylation containing sLex and sLea, both epitopes 
recognized by selectins. The expression of these epitopes is correlated with tumor progression 
and metastasis in human (Nakamori et al., 1993). In addition, human carcinoma cell lines, like 
LS180, express sialomucins that can bind L- and P-selectins (Mannori et al., 1995). All three 
selectins were able to bind to carcinoma cell lines in a calcium dependent manner (Mannori et 
al., 1995) and this recognition was abolished by O-sialoglycoprotease, a mucin endopeptidase 
(Borsig et al., 2001a). Mucins had separate binding sites for each selectin, allowing cross-
binding of a mucin molecule by more than one selectin. Leukocytes, platelets and endothelial 
cells can then interact with tumor cells at the same time (Kim et al., 1999). In this project, we 
were mostly interested in the role of L-selectin during cancer progression. 
 
E-selectin expressed by endothelial cells and metastasis 
Sialyl-Lewis x/a structures were shown to be specifically recognized by E-selectin and studies 
describe the presence of E-selectin ligands on carcinoma cells (Majuri et al., 1995). The 
presence of mucin cancer antigen binding to E-selectin has been detected in the blood of 
colon carcinoma patients (Zhang et al., 1994). Moreover, the metastatic potential of colon 
carcinoma cell lines in nude mice increased with the expression of sLex (Izumi et al., 1995). 
Interestingly, overexpression of E-selectin in the mouse liver redirected metastasis of 
carcinomas that normally colonize the lungs (Biancone et al., 1996). E-selectin is a major 
mediator for facilitation of metastasis. 
 
P-selectin expressed by platelets and metastasis  
Carcinomas bind to activated platelets expressing P-selectin (Mannori et al., 1995) and in P-
selectin deficient mice, metastasis is attenuated (Kim et al., 1998). This P-selectin-dependent 
facilitation of human carcinoma metastasis in immunodeficient mice is due to interaction of 
platelets with mucins borne by the tumor cells and this process can be blocked by heparin 
(Borsig et al., 2001a). Studies in immunocompetent mouse gave the same results in terms of 
attenuation of metastasis but the ligand was shown to be a sulfatide on tumor cells (Borsig et 
al., 2002; Garcia et al., 2007). 
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L-selectin on lymphocytes surface and metastasis 
The contribution of L-selectin to metastasis has recently been observed. In the absence of L-
selectin, metastasis of human adenocarcinoma cells in immunodeficient mice was attenuated 
(Borsig et al., 2002) (Figure 10). This result was unexpected because expression of L-selectin 
ligands was thought to provoke tumor cell elimination by leukocytes (Kim and Varki, 1997).  
 
 
 
Figure 10: L-selectin deficiency attenuates metastasis of human adenocarcinoma cells in immunodeficient mice. 
Figure reprinted from (Borsig et al., 2002).  
 
In the P- and L- double selectin deficient mice, metastasis was further attenuated in 
comparison to single deficient mice (Borsig et al., 2002). Thus, contribution of P- and L-
selectin seems to be synergistic during metastasis formation. L-selectin promotes recruitment 
of leukocytes to tumor cells and their survival following their entrance in the vasculature. 
This indicates a local involvement of leukocytes in establishment of metastatic foci. 
Moreover, in L-selectin deficient mice, association of Mac-1+ leukocytes with tumor cells 
was reduced and tumor survival diminished (Läubli et al., 2006) (Figure 11).  
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Figure 11: Association of tumor cells with leukocytes in the wt and L-selectin deficient models. Figure reprinted 
from (Läubli et al., 2006). 
 
L-selectin is constitutively expressed by most leukocytes (Kansas, 1996). The role of 
leukocytes in the facilitation of metastasis by L-selectin seems to be downstream from P-
selectin mediated interaction of platelets with tumor cells. The effect of L-selectin was 
observed even in immunodeficient mice, indicating that granulocytes and/or monocytes are 
likely implicated in this metastatic process. Leukocytes may bind platelet-carcinoma emboli 
through L-selectin interactions (Figure 12). This leukocyte-tumor cell association could 
promote the extravasation by two means: 1) by increasing the size of the tumor embolus 
which facilitates its mechanical trapping in the microvasculature, 2) by helping tumor cells to 
extravasate in a L-selectin dependent manner. This second possibility for the observed 
contribution of leukocytes to metastasis is suggested by the capacity of L-selectin-positive 
leukocytes to transmigrate through activated endothelium expressing L-selectin-ligand 
(Hickey et al., 2000; Ley, 2002; Worthylake and Burridge, 2001). 
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Figure 12: Possible selectin-tumor cell interactions during malignancy. Hypothetical model showing all the 
interactions that can take place between carcinoma cells carrying selectin ligands and selectins expressed on 
activated platelets, activated endothelial cells and leukocytes. All these interactions have been shown to occur in 
vitro and some have been seen in vivo. Figure reprinted from (Borsig, 2004). 
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3 Aim of the project 
Alteration of tumor cell-surface glycosylation is correlated with enhanced metastasis in 
patients with colon adenocarcinoma. Metastasis is facilitated by the tumor cell embolus 
formation consisting of blood platelet aggregates and leukocytes around the tumor cells. 
Carcinomas expressing sLex carbohydrate structures can potentially bind P- and L-selectins 
found at the surface of platelets and leukocytes respectively. The adhesion of platelets to 
tumor cells is primarily mediated by P-selectin as previously shown. The observation that 
metastasis was attenuated in the absence of L-selectin implicates leukocytes to be actively 
involved in the facilitation of metastasis. 
The aim of this project was to investigate the nature and function of leukocytes in the early 
phase of metastasis. Three specific objectives were pursued in this work: 
1) Which subpopulation of leukocytes contributes to the metastatic process? 
2) How do the leukocytes assist tumor cells during establishment of metastatic foci? 
3) Do they affect their migration?  
Since there is little known about the contribution of leukocytes to metastasis, this project was 
rather challenging for me. 
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Abstract 
 
Metastasis is supported by the formation of a tumor cell embolus, consisting of aggregated 
platelets and leukocytes adherent on tumor cells. While interactions between tumor cells and 
platelets and their contribution to metastasis have been studied, the participation of leukocytes 
in this mechanism remains to be elucidated. We previously showed that the absence of L-
selectin on leukocytes leads to an attenuation of metastasis and to a reduced association 
between leukocytes and tumor cells. Here, we study the contribution of leukocytes to 
metastasis depending on L-selectin expression in vitro and in vivo. Granulocytes / monocytes 
were shown to help tumor cells to extravasate through the vascular endothelium in an L-
selectin dependent manner. This process affects the endothelial cell layer and the vascular 
permeability. Depletion of monocytes led to an attenuation of metastasis, clearly indicating 
leukocytes as facilitators in metastasis. Taken together, leukocytes promote tumor progression 
during the early step of metastasis.  
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Introduction 
 
Hematogenous metastases are the main cause of cancer-related death. To metastasize, tumor 
cells have to enter the bloodstream, evade innate immune surveillance and extravasate 
through the vascular endothelium. Tumor cell extravasation in carcinoma metastasis is known 
to be facilitated by the formation of platelet aggregates and leukocytes around tumor cells. 
These so called tumor cell emboli contribute to the establishment of metastatic foci (Honn et 
al., 1992b; Karpatkin and Pearlstein, 1981). The mechanism of platelet binding to tumor cells 
and its contribution to metastasis has been investigated. Coagulation and presence of platelets 
facilitated tumor cell metastatic spread in the pulmonary vasculature (Im et al., 2004). 
Platelets were shown to protect the tumor cells from the clearance by NK cells (Nieswandt et 
al., 1999) and to promote metastasis through P-selectin-mediated interactions with carcinoma 
cell-surface mucin ligands (Borsig et al., 2001a). Endothelial P-selectin expressed on the 
vasculature contributed also to the formation of hematogenous metastases (Ludwig et al., 
2004). Vascular cell adhesion molecules P- and E-selectin were shown to contribute to 
metastasis by binding selectin ligands on tumor cells (Biancone et al., 1996; Garcia et al., 
2007; Ludwig et al., 2004). Indeed in the absence of P-selectin, metastasis was attenuated 
(Borsig et al., 2001a). Leukocytes were associated with tumor cells on lung tissues but their 
function in the tumor cell emboli remained to be elucidated. Tumor microenvironment plays a 
major role in the contribution of leukocytes to tumor progression (Coussens and Werb, 2002; 
Fidler, 2002; Liotta and Kohn, 2001). Leukocytes have antitumor activity but increasing 
evidence indicates their potential role in supporting tumor progression (de Visser et al., 2006). 
Indeed, neutrophils were shown to enhance metastasis of tumor cells in several carcinomas 
(Queen et al., 2005; Tazawa et al., 2003; Welch et al., 1989). Interestingly, skin 
carcinogenesis was induced by inflammatory cells (Coussens et al., 2000). Clinical data show 
a correlation between high leukocytic infiltration into solid tumors and poor outcome of 
patients (Coussens and Werb, 2002).  
L-selectin is constitutively expressed by granulocytes, monocytes, T and B cells and NK cells 
(Kansas, 1996) and mediates the rolling of leukocytes on endothelial cells as well as their 
binding to the endothelium during inflammation (Kansas, 1996; Ley, 2002; Sperandio et al., 
2003). Interestingly, L-selectin ligands were found in the microenvironment of tumor cells 
being expressed on activated endothelium and on tumor cells MC-38 (Läubli et al., 2006). 
The absence of L-selectin attenuated metastasis in mice (Borsig et al., 2002), thereby directly 
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implicating leukocytes to this process. The effect of L-selectin was observed even in 
immunodeficient mice (T- and B- cell deficient), indicating that innate immune cells are most 
likely implicated in this metastatic process. Moreover, in the absence of L-selectin, the 
association of leukocytes with tumor cells was reduced. L-selectin promoted recruitment of 
leukocytes to tumor cells and their survival following their entrance in the vasculature 
(Laubli, Stevenson et al. 2006).  
The present study was undertaken to identify the subtype of leukocytes implicated in the 
metastatic process and to define their role. We were able to show that both granulocytes and 
monocytes facilitate tumor cell transmigration in an L-selectin dependent manner. 
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Materials and methods 
 
Syngeneic mouse/tumor model 
Control wild-type (wt) C57BL6 mice were from The Jackson Laboratory (Bar Harbor, ME) 
and L-selectin-deficient mice (L-sel-/-) were backcrossed into the C57BL6 background as 
described previously (Borsig et al., 2002). Syngeneic MC-38 murine colon carcinoma cells 
(grade III) were derived from C57BL6 mouse strain (Borsig et al., 2002). Colon carcinoma 
cells were isolated as a mixed population of cells stably expressing green fluorescent protein 
(GFP) designated MC-38GFP (Borsig et al., 2002). 
 
In vivo detection of leukocytes associated with tumor cells 
Mice were intravenously injected with 4 x 105 MC-38GFP cells and lungs prepared at various 
time points as described previously (Borsig et al., 2001a). Frozen lung sections were stained 
with a monoclonal anti-CD11b antibody (Crockett-Torabi et al., 1995) from Becton 
Dickinson directly coupled with Alexa660 and anti-Ly6G-biotin antibody (Becton 
Dickinson), followed by Streptavidin-Alexa 546 (Molecular Probes). Finally, monoclonal 
antibody against BM8 was added (BMI, Basel), followed by goat-anti-rat-Alexa594 
(Molecular Probes). Sections were analyzed on a Leica SP2 confocal laser scanning 
microscope. Serial section image stacks of a tissue section were acquired by Leica SP1 
confocal laser scanning microscope and were analysed by Imaris® software (Bitplane AG, 
Zürich, Switzerland). At least ten images for every lung/time point were analyzed. 
 
Isolation of lung microvascular endothelial cells  
Mouse lung microvascular endothelial cells were isolated using a positive immunomagnetic 
selection (Wang et al., 2005). Briefly, 6 lungs were minced and digested with 0.1 % 
collagenase A (Gibco, Invitrogen) for 1 h at 37°C. Digested tissues were filtered through 100 
µm and 40 µm sterile meshes (BD Biosciences). The cell suspension was incubated with rat 
anti-mouse CD31-FITC -0.4 µg per 1.106 cells- (BD PharmingenTM) and then incubated with 
10 µl/107 cells of magnetic beads coated with anti-FITC isotype 1 (MACS Miltenyi Biotec). 
Cells bound to the beads were recovered with a magnetic separator (MS column, MACS 
Separation columns, Miltenyi Biotec) following manufacturer’s instructions and resuspended 
in EC medium (DMEM low glucose containing 20 % FCS, 100 µg/ml of porcine heparin 
(Sigma), 100 µg/ml of endothelial cell growth supplement ( BD Biosciences) and nonessential 
amino acids, HEPES, L-glutamine and antibiotics at standard concentrations). Cells were then 
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plated on 0.1 % gelatin (Sigma) coated six-well plates. Medium was changed every day the 
first 4 days in order to remove all contaminating non-adherent cells. At day 10, the cells were 
passaged on bigger plates and used for experiments at passages 2-5. 
 
Isolation of granulocytes on a Percoll gradient  
The isolation of granulocytes was performed on a three-layer Percoll gradient of 78 %, 69 % 
and 52 % Percoll (Boxio et al., 2004). After centrifugation, granulocytes were collected at the 
78-69 % interface followed by a lysis of contaminating red blood cells with PharMlyse (BD 
Pharmingen). The purity of the obtained granulocytes was always above 95 % among 
leukocytes.  
 
Granulocytes and monocytes derived from clones of immortalized bone marrow cells 
Granulocytes and monocytes from wt or L-sel-/- mice were obtained in high number by 
conditional derivation of primary murine marrow progenitors (Sykes and Kamps, 2001). 
Briefly, bone marrow from the femur and tibia of wt and L-sel-/- mice were isolated after 
ammonium sulfate lysis of erythrocytes and centrifugation onto a Ficoll-Paque gradient 
(Ficoll-Paque PLUS, Amersham). Ficoll-purified progenitors were then pre-stimulated 48h in 
25 ng/ml murine SCF, 10 ng/ml murine IL-3 and 20 ng/ml murine IL-6 (cytokines from Cell 
sciences) for an optimized retroviral transfection. The marrow progenitors were retrovirally 
infected by spinoculation in the presence of lipofectamine (Invitrogen). The retroviral vector 
expressed the fusion oncoprotein E2a/Pbx1 fused to the hormone binding domain (HBD) of 
the estrogen receptor for its conditional expression. The infected progenitors were cultured in 
RPMI 1640 from Gibco with 10 % FCS, 1 % GM-CSF-conditioned medium from B16 
melanoma expressing the Csf2 cDNA and 1 µM estrogen from Sigma. Immortalized myeloid 
progenitors were selected by removal of nonadherent progenitor cells every 3 days to a new 
well during 3 weeks. Differentiation of progenitors committed exclusively to granulocytes or 
monocytes required cloning performed using 96-well microtiter plates. Clones were identified 
by screening for Gr-1 expression after retrieval of estradiol from the culture medium. 
 
Preparation of tumor-conditioned medium (TCM) 
Tumor cells MC-38 (100’000/ml) were added to endothelial cells grown till confluency in 
DMEM 5 % FCS for 24 hours. TCM was harvested, centrifuged and stored at -20°C until use. 
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Assessment of tumor cell transmigration 
Mouse lung microvascular endothelial cells were grown in 0.3 ml EC medium (1.7x105 
cells/ml) in the upper chamber of a 6.5 mm diameter insert (8 µm pore size Falcon TM cell 
culture inserts, Becton Dickinson Labware), with 0.8 ml of EC medium in the lower chamber 
at 37°C for 24 h until a confluent monolayer was reached. For leukocyte-assisted tumor cell 
MC-38GFP migration assay, granulocytes and monocytes derived from clones of 
immortalized bone marrow cells or granulocytes isolated on a Percoll gradient were used. 
Granulocytes (200’000), monocytes (40’000) were mixed to tumor cells MC-38GFP (20’000) 
in a total volume of 0.3 ml DMEM with 5 %FCS and added to the upper chamber above the 
endothelial cell monolayer. 0.5 ml of TCM was added to the lower chamber. After 16 hours 
of co-culture, inserts were scraped to remove non migrated tumor cells, fixed and stained with 
Dapi. Migrated tumor cells were counted on 40 view fields under the fluorescence microscope 
(Zeiss) at 40 x magnification. Migrated leukocytes were collected in the lower chamber and 
counted. Statistical significance was determined by the Student’s t test. 
 
Cytoskeletal remodeling 
To demonstrate that pulmonary endothelial cells are capable of responding to the presence of 
tumor cells, granulocytes and monocytes-mediated activation, we investigated the distribution 
of F-actin as described previously (Zarbock et al., 2006). Briefly, 20’000 endothelial cells 
were allowed to grow to confluency on gelatin-coated glass coverslips for 48 hours. 20’000 
tumor cells in the presence of granulocytes (200’000) and monocytes (40’000) were added in 
DMEM with 5 % FCS or in TCM. Endothelial cells alone served as control. After 4 h of 
incubation at 37°C, the cells were fixed (PFA 3 %), permeabilized (0.1 % saponin, Sigma-
Aldrich) and stained with FITC-phalloidin (40µg/ml, Invitrogen Corp.). Coverslips were 
mounted on glass slides. The analysis was performed using a Leica SP5 confocal laser 
scanning microscope and Imaris® software (Bitplane AG, Zürich, Switzerland). Cell areas 
and intensities were determined with ImageJ program (EMBL). 
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Pulmonary microvascular permeability 
Determination of pulmonary microvascular permeability in wt and L-sel-/- mice was 
performed using the Evans Blue dye extravasation technique (Reutershan et al., 2006). 
Briefly, 400’000 MC-38 tumor cells were injected intravenously in mice for 24 hours. 2 mg 
of Evans Blue (Sigma-Aldrich) was injected intravenously 30 minutes prior to euthanasia. 
Lungs were perfused through the spontaneously beating right ventricule to remove 
intravascular dye. Lungs were removed and homogenized. Evans Blue was extracted by 
incubation with 2 volumes formamide at 60°C for 18 hours. After centrifugation, the optical 
density of the supernatant was measured by 620nm. Extravasated Evans Blue in micrograms 
was determined in the different animal groups. 
 
Clodronate depletion of monocytes and experimental metastasis assay 
Mice were intravenously injected with 2 mg of clodronate loaded liposomes as described 
previously (Zeisberger et al.). After 48 h mice were intravenously injected with  
3.5 x 105 MC-38GFP cells. After 28 days, mice were sacrificed and metastasis was evaluated 
by counting of lung foci and/or detecting of GFP fluorescence in lung homogenate as 
previously described (Borsig et al., 2002).  
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Results 
 
L-selectin mediates association of innate immune cells to metastatic foci  
Attenuation of metastasis observed in L-selectin deficient mice identified leukocytes in this 
process. Tumor cells were shown to be associated with leukocytes in an L-selectin dependent 
manner (Läubli et al., 2006). To determine the nature of the immune cells in the vicinity of 
tumor cells in the lungs, we analyzed tumor associated leukocytes in lung tissues. For this, 
lungs were fixed at different time points following injection of tumor cells. Lung sections 
were stained with antibodies recognizing different populations of leukocytes. Monocytes were 
detected for their positive Mac-1 staining, granulocytes for Gr-1 and Mac-1 and macrophages 
for BM8. Tumor cells were associated with monocytes, macrophages and granulocytes and 
the contact of these immune cells with tumor cells was reduced in lungs of mice deficient for 
L-selectin 12 till 36 hours after tumor injection (Figure 1). These results suggest that L-
selectin on granulocytes / monocytes / macrophages has an important role in the metastatic 
spread of tumor cells. 
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Figure 1: Cell-cell contact between tumor cells and immune cells is reduced in mice deficient for L-selectin. The 
figures show the percentage of contact between tumor cells and immune cells on lung sections coming from wt 
(A) and Lsel-/- mice (B) at different time points following tumor cell injection. P<0.05 (unpaired Student’s t 
test). Results shown were taken from the thesis of Peter Jäggi and Heinz Läubli. 
 
 
Leukocytes enhance transendothelial migration of tumor cells in an L-selectin dependent 
manner 
Monocytes and granulocytes have been shown to be associated with tumor cell emboli in an 
L-selectin dependent manner in lung sections in situ (Figure 1). In order to investigate the role 
of L-selectin and the function of leukocytes associated with tumor cells, we proceeded to a 
transmigration assay in vitro. It was of interest to determine whether granulocytes (G) or 
monocytes (M) or both affect the migratory capacities of tumor cells through the endothelium. 
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For this, tumor cells were added to an endothelial cell monolayer in the presence of 
granulocytes and/or monocytes and their migratory capacities were determined after 16h of 
co-culture (Figure 2).  
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Figure 2: Granulocytes and monocytes enhance the transmigration of tumor cells through endothelial cells (EC) 
in an L-selectin dependent manner. Cells were mixed at the following ratios: for one part of tumor cell (20’000), 
ten parts of granulocytes (200’000) and two parts of monocytes (40’000) were added. Migration of tumor cells 
alone was normalized at 10 cells/view field. The figure is a summary of at least three independent experiments. * 
P<0.05, ** P<0.001 (unpaired Student’s t test). Columns, mean; bars, SEM. 
 
Tumor cell migration was facilitated by both classes of leukocytes, granulocytes and 
monocytes, in an L-selectin dependent manner (Figure 2). We observed a 30 % increase of 
tumor cell migratory capacities by the presence of granulocytes. Interestingly, this positive 
effect in the presence of leukocytes was amplified by monocytes and granulocytes added 
together with tumor cells. In this case, an increase of 60 % compared to basal migratory 
capacities of tumor cells was observed. Innate immune cells derived from L-selectin deficient 
mice were not able to potentiate tumor cell migration, regardless of the mixture. Thus, L-
selectin on leukocytes is implicated in the promotion of tumor cell migration through 
endothelium. 
In order to perform this assay, we used monocytes and granulocytes cloned and differentiated 
from bone-marrow progenitor cells (Sykes and Kamps, 2001) because it was not possible to 
isolate mouse monocytes in a high number. We performed the same assay using blood 
granulocytes isolated on a Percoll gradient and tumor cell transmigration was affected in the 
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same way independently of the use of blood granulocytes or granulocytes derived from 
clones. Thus granulocytic and monocytic clones of immortalized bone marrow cells possess 
the same functions as native leukocytes. The ratio of monocytes to tumor cells was crucial for 
their migration. Indeed, when five parts of monocytes for one part of tumor cells were used, 
the positive effect on migration was abolished (Supplementary Figure 1). Thus, monocytes 
seem to have a pivotal role in the transmigration process. Interestingly, tumor cell migration 
was in correlation with the number of migrating leukocytes. Indeed, we observed that 
granulocytes derived from wt mice in interaction with tumor cells and endothelial cells are 
functionally more active and migrated in a higher proportion through endothelial cells as 
compared to granulocytes derived from L-selectin deficient mice (Supplementary Figure 2). 
This suggested that leukocytes could be activated in an L-selectin dependent manner and 
possibly enhanced tumor cell extravasation. Moreover, tumor cell conditioned medium 
(TCM), prepared from incubation of tumor cells with endothelial cells, and used at the bottom 
well of our assay may contain chemotactic agents important for tumor cell migration. 
These findings show that L-selectin mediated interactions of leukocytes at the site of 
extravasation contribute to transendothelial migration of tumor cells.  
 
L-selectin dependent tumor cell transmigration affects endothelium 
Leukocytes enhanced tumor cell migration through endothelial cells. To investigate whether 
the endothelial cell monolayer was affected by the presence of tumor cells and leukocytes, we 
proceeded to a co-culture assay. Tumor cells and leukocytes were added to endothelial cells 
(EC) grown on confluency on coverslip for 4 hours and the EC response was analyzed by 
staining for phalloidin binding to actin filaments (Figure 3 A and B). 
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Figure 3: Endothelial cell response to addition of tumor cells, granulocytes and monocytes was investigated by 
F-actin localization. F-actin was localized by phalloidin staining (green). A In case of endothelial cells alone, the 
monolayer stayed intact. B Tumor cells, granulocytes, monocytes activated the endothelial cells at various sites. 
Endothelial cells appear in a polygonal retracted shape (arrow in the left panel). Images are representative of 
three independent experiments with similar results. C Area of the retracted EC in comparison with normal EC in 
an intact monolayer defined as described in Materials and Methods. * P<0.05, ** P<0.005. Columns, mean; 
bars, SEM.  
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In the presence of tumor cells and leukocytes EC layer retracted at many places and a general 
separation of adjacent cells was observed in many locations (Figure 3B, left panel). 
Endothelial cells appeared in a polygonal retracted shape with increasing intensities of 
staining for actin bundles at the cell border (Figure 3B, arrows in left and right panels). This 
EC retraction follows a reorganization of the actin cytoskeleton and a formation of stress 
fibers (Zarbock et al., 2006). At these sites of EC barrier interruptions, the cells were 
significantly smaller (Figure 3C). The retraction of the cells was not dependent on L-selectin 
expression of leukocytes. The presence of TCM also led to a retraction of the endothelial cell 
layer. This result shows that tumor cells in the presence of leukocytes may be able to activate 
endothelial cells by provoking their retraction.  
To further investigate this finding in vivo, the pulmonary vascular permeability was tested 
after injection of tumor cells. Evans Blue was injected 30 minutes preceding the perfusion of 
the lungs. The amount of Evans Blue in lung homogenates was then quantified as described in 
the Materials and Methods section (Figure 4). 
 
 
 
Figure 4: Pulmonary microvascular permeability is enhanced in an L-selectin dependent manner. The figure 
shows the permeability of the lungs 24 h following tumor cell injection. * P<0.05 (unpaired Student’s t test),  
n = 4. Columns, mean; bars, SEM 
 
The vascular leak of the lungs after the injection of tumor cells was enhanced by 65 % in the 
wt mice. There was no enhancement observed in absence of L-selectin. Thus L-selectin 
presence on leukocytes correlates with an enhancement of the vascular permeability. 
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Leukocytes and tumor cells are able to induce a physiological change of the endothelial 
barrier, most probably at the extravasation site of tumor cells. 
These data show that tumor cells and leukocytes alter the EC layer in vitro. Confirming this 
observation, L-selectin on leukocytes increased the vascular permeability after tumor cell 
injection mice. These findings suggest that during the process of tumor cell extravasation 
endothelial cells are responsive to the presence of leukocytes and tumor cells thereby 
modulating their physiological properties in an L-selectin dependent manner. 
 
In vivo depletion of monocytes leads to a reduction of metastasis 
The finding that L-selectin on leukocytes in the presence of tumor cells modulates the 
endothelial cell layer response led us to suggest that leukocytes contribute also to 
extravasation of tumor cells through the endothelial barrier in vivo. Previously, we observed 
that the depletion of L-selectin in vivo by injection of a functionally blocking antibody 6-12 
hours after tumor cell injection led to an attenuation of metastasis (Läubli et al., 2006). When 
granulocytes were depleted by injection of Ly6G Ab in mouse (Sitia et al., 2002), no 
attenuation of metastasis was observed. Depletion of granulocytes did not result in an 
attenuation of metastasis, most probably due to the fact that it lasted 5 days in the circulation. 
Indeed, granulocytes were not in the circulation within the time frame of the initial clearance 
of tumor cells (Läubli et al., 2006). More work is needed to optimize the depletion of 
granulocytes in order to delineate their action in vivo. To test whether monocytes contributed 
to metastasis, mice were intravenously injected with clodronate encapsulated in liposomes. 
Forty-eight hours following monocyte depletion, tumor cells were intravenously injected. 
After 4 weeks, metastasis was highly attenuated in monocyte-depleted wt mice as shown by 
quantification of the metastatic foci (Figure 5-A and B). The level of metastasis was even 
lower than the one observed in L-selectin deficient mice. Thus circulating monocytes promote 
metastasis in vivo. The function of monocytes in metastasis was confirmed by evaluating the 
presence of monocytes in the vicinity of tumor cells by immunofluorescence staining of lung 
sections of these depleted mice (Figure 5-C). Monocytes (F4/80+-Mac-1+) were in close 
proximity of tumor cells in non depleted lungs (Figure 5-C, left panel). In clodronate-depleted 
lungs, the association of monocytes with tumor cells was highly reduced (Figure 5-C, right 
panel). Moreover, on lung sections of these depleted mice, total number of monocytes was 
highly reduced and the total number of tumor cells was decreased by factor 3 (data not 
shown). Alveolar macrophages stayed untouched in both wt and depleted mice (data not 
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shown). Taken together, these results strongly indicate a major role of monocytes in the 
formation of metastases. 
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Figure 5: Depletion of monocytes in vivo attenuates metastasis. A, wt and monocytes depleted mice were 
injected with MC-38GFP cells and mice were euthanized after 26 days and dissected lungs were evaluated for 
metastatic foci. B, The extent of metastasis was analysed by GFP fluorescence read out in lung homogenates. 
P<0.001 (unpaired Student’s t test). C, Mice depleted of monocytes by clodronate liposome injection were 48 h 
later injected with 3.5 x 105 MC-38GFP cells and after another 24 h sacrificed. Representative images of lung 
sections stained with anti-CD11b antibody (red) and GFP tumor cells (green) and nuclei stained with DAPI 
(blue) are presented. Injection of clodronate liposomes led to reduced monocyte association with tumor cells 
(right panel), while in controls (empty liposomes) association with tumor cells could readily be seen (left panel). 
Note, that monocytes/macrophages could be detected in the depleted lungs, but are not tumor associated (arrow 
in the right panel). 
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Discussion 
 
Hematogenous metastasis is facilitated by tumor cell-platelet-leukocyte embolus formation. 
Previous studies showing an enhancement of selectin ligands on cancer cells associated with 
tumor progression suggested an involvement of selectins in cancer development (Hakomori, 
1996; Kannagi et al., 2004; Kim and Varki, 1997). Endothelial E- and P-selectin were shown 
to promote metastasis in several mouse models (Biancone et al., 1996; Borsig et al., 2002; 
Kannagi et al., 2004). Platelet-tumor cell interactions was shown to be primarily mediated by 
P-selectin, while the inhibition of these interactions was associated with reduction of 
metastasis (Borsig et al., 2001a; Borsig et al., 2002; Garcia et al., 2007). Our previous 
findings, that L-selectin deficiency is associated with attenuation of metastasis, clearly 
implicated leukocytes in this process (Borsig et al., 2002). L-selectin promoted tumor cell 
survival, most probably by action of leukocytes found to be associated with tumor cells 
(Läubli et al., 2006). Here we provide the first evidence that cell-cell contacts among tumor 
cells, granulocytes / monocytes are L-selectin dependent and are associated with leukocyte 
recruitment to metastasizing tumor cells in the lung (Figure 1). The association between 
immune cells and tumor cells has been shown to correlate with metastasis (Coussens et al., 
2000; Lin et al., 2001; Queen et al., 2005; Tazawa et al., 2003). Neutrophil infiltration of 
tumors led to the acquisition of a metastatic phenotype of otherwise benign murine 
fibrosarcoma cells (Tazawa et al., 2003). Moreover, tumor associated monocytes have been 
shown to directly participate in tumor progression (Lin et al., 2001). Macrophages recruited at 
the site of primary tumor are able to increase the metastatic potential of tumor cells. 
Interestingly, bone marrow-derived cells can lead to skin carcinogenesis (Coussens et al., 
2000). Macrophages recruited to the site of primary tumor can increase the metastatic 
properties of tumor cells. Their presence close to tumor cells seems to be determinant for the 
further outcome of tumor cells. Little is known on the role of circulating monocytes in 
metastasis. Interestingly circulating monocytes were associated with tumor cells suggesting 
that they could participate to the formation of metastases in our mouse model. 
To elucidate the function of the associated leukocytes, we first focused on the role of 
granulocytes and monocytes in a transmigration assay. We suggest that monocytes and/or 
granulocytes could assist tumor cells to breach the endothelial barrier. We could show that 
granulocytes / monocytes promote tumor cell transmigration through endothelium (Figure 2). 
The link between inflammation, presence of granulocytes and the enhancement of tumor 
migration has already been suggested (Welch et al., 1989). For instance, neutrophils were 
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enhancing the metastatic potential of rat adenocarcinoma cells, by facilitating invasion into 
basement membrane (Welch et al., 1989). We showed that granulocytes and monocytes 
promoted tumor cell migration through endothelium in an L-selectin dependent manner 
(Figure 2) suggesting that L-selectin affects metastasis at the site of tumor cell extravasation. 
The observed tumor cell migration differences could explain the attenuation of metastasis 
observed in mice deficient for L-selectin and could implicate direct cell-cell contact between 
tumor cells, innate immune cells and endothelium. We made then the interesting observation 
that this enhanced tumor cell transmigration was due to a physiological change of underlying 
endothelial cells. Endothelial cells that line the vasculature have close cell-cell association and 
their permeability is regulated by many growth factors and cytokines (Stockton et al., 2004). 
We observed a retraction of the endothelial layer characterized by altered cell-cell contacts 
(Figure 3A and B) and a high dependence on cell-cell contacts between leukocytes-tumor 
cells and endothelial cells.  The enhancement in vascular permeability was L-selectin 
dependent (Figure 4). Thus, endothelial cells seem to be a key player in the facilitation of 
metastasis. Tumor cells have been shown to cause endothelial cell retraction (Honn et al., 
1994; Lee et al., 2003). In agreement with our findings, other groups described a loss of 
endothelial cell integrity during tumor cell transmigration (Heyder et al., 2002; Weis et al., 
2004). Indeed, the production and release of VEGF by tumor cells led to a breakdown of 
endothelial barrier function through a disruption of adherent junctions. This, in turn, caused 
rapid tumor cell extravasation and metastasis (Weis et al., 2004). Another study showed that 
the vascular endothelium was irreversibly damaged at the site of tumor cell extravasation by 
using real-time visualization of tumor cell/endothelial cell interactions during transmigration. 
The damaged endothelium was undergoing apoptosis (Heyder et al., 2002). In our assay, 
TCM also had an effect on endothelial cell activation (Figure 3B). We suggest that TCM 
contains chemokines -being secreted by tumor or endothelial cells or both- that modulate the 
endothelial cell layer. TCM, leukocytes and tumor cells are pivotal in EC layer activation. 
When only one component is absent, the endothelial cell layer is less affected. Both cell-cell 
contact and cytokine secretion may be relevant also for the transmigration in vivo.  
Moreover, the direct role of monocytes was confirmed in vivo. The depletion of circulating 
monocytes led to attenuation of metastasis (Figure 5), documenting their essential 
contribution to the promotion of metastasis. Recruited circulating monocytes may facilitate 
tumor progression by increasing the migratory capacities of tumor cells and by acting on the 
permeability of the endothelial cells. 
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In conclusion, our study proposes recruited circulating monocytes as pivotal partners of tumor 
cell metastasis and L-selectin as a key contact molecule between leukocytes, tumor cells and 
endothelial cells for the establishment of metastasis. 
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Supplementary Figures 
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Supplementary Figure 1: Migration of tumor cells in the presence of granulocytes and monocytes at different 
ratios. The figure presents the transmigration of tumor cells through EC in the presence of granulocytes and 
monocytes. Five parts (5x) or two parts (2x) of monocytes were added for one part of tumor cells. Migration of 
tumor cells was normalized at 10 cells/view field for the migration of tumor cells alone. This figure is 
representative of six independent experiments. p<0.005 (unpaired Student’s t test). Columns, mean; bars, SEM. 
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Supplementary Figure 2: Migration of leukocytes accompanying tumor cell transmigration. The figure 
presents the transmigration of leukocytes through EC in the presence of tumor cells.  
** P<0.005, * P<0.05 (unpaired Student’s t test). Columns, mean; bars, SEM. 
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Additional data 
 
Endothelial cell isolation 
 
We studied experimental metastasis in a mouse model, where tumor cells metastasize 
primarily to the lungs. Therefore, to study the role of leukocytes in initiation of metastasis, 
endothelial cells were isolated from mouse lung tissue. 
 
Endothelial cells were isolated according to the Methods previously described in Manuscript1 
(Wang et al., 2005). The isolation and long-term culture of primary murine lung endothelial 
cells was difficult due to overgrowth of contaminating cells, in particular fibroblasts. Here is a 
brief summary of the optimized protocol for the isolation of primary lung endothelial cells: 
• we were not proceeding to HistoDenz (containing metrizamide) step of EC enrichment 
by lymphocytes retrieval as we did not find any advantage to this step (Fields et al., 
1998). Indeed, the co-purified lymphocytes, binding also CD31, were found in the 
supernatant of our culture (tested by CD5 expression) and easily retrieved by 
aspiration and washed from culture medium, 
• we were doubling the concentration of primary antibody CD31-FITC and reducing the 
concentration of the beads (Tiruppathi et al., 2002), 
• we always tried to obtain a single-cell suspension before addition of primary antibody 
in order to avoid the co-purification of unwanted cells, 
• we cultured EC on gelatin, not on matrigel, 
• we were not using any treatment containing trypsin-EDTA solutions, because the 
murine CD31 epitope could be damaged by this enzymatic treatment (Marelli-Berg et 
al., 2000). 
 
Following isolation, EC grew in several clusters that formed a monolayer within 10 days and 
showed the characteristic cobblestone morphology (Figure 1A). Expression of CD31 surface 
molecule, an EC marker, was performed by the help of flow cytometry. It indicated the purity 
of the isolated EC (Figure 1B). 
Finally from 6 lungs, 20x106 pure endothelial cells were obtained (about 15 days after the 
isolation, 3rd passage). 
65 
 
 
 
A 
 
B 
 
 
Figure 1: Isolated mouse endothelial cells. (A) This picture shows the typical cobblestone morphology of the 
isolated endothelial cells. (B) Endothelial cells were stained with CD31-FITC and analyzed by flow cytometry. 
CD31 staining is represented by a bold solid line. Filled area represents control unstained cells. EC population 
was 100 % pure. 
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Granulocyte and monocyte isolation 
 
In order to use granulocytes and monocytes in our co-culture experiments, we needed to 
isolate them in high number and in a non activated state. 
 
Method 1: 
Neutrophils were first isolated from the peripheral blood mononuclear cells by using a 
cocktail of antibodies and a magnetic column as described by Cotter and his colleagues 
(Cotter et al., 2001). Briefly, mouse blood was collected by cardiac puncture and platelets 
were removed after dextran sedimentation of erythrocytes (1% dextran in PBS, 10’ at 37°C). 
Erythrocytes were lysed by ammonium chloride solution (PharmLyse, BD Biosciences, San 
Diego, CA). Blood mononuclear cells were then incubated with a cocktail of antibodies 
against specific markers for unwanted cells, lymphocytes and monocytes, followed by 
incubation with secondary antibody coated magnetic beads. The antibodies used were CD45R 
(B220) for B-lymphocytes, CD5 for T and B lymphocytes, CD2 for T and B lymphocytes and 
NK cells, F4/80 for mature monocytes and ICAM-1 for monocytes. Neutrophil-rich effluent 
was then collected, stained with the marker Gr-1 and analyzed by flow cytometry. 
The depletion of monocytes had to be optimized and finally, a pure population of neutrophils 
with a yield of 200’000 neutrophils / ml blood was obtained. Unfortunately, the obtained 
neutrophils were activated. A characteristic loss of size and granularity by analyzing the cells 
before and after isolation by flow cytometry was observed. In the presence of PMA, a known 
activator of granulocytes, isolated cells were even not able to shed L-selectin anymore 
(Crockett-Torabi et al., 1995). The paper published by Cotter and his colleagues claimed that 
isolated neutrophils were still L-sel +/+, a phenomenon that we were never able to reproduce 
even after optimizing and controlling each step for the presence of potential activators. This 
activation could occur during the negative selection. 
 
Method 2: 
Another method was used by isolating granulocytes on a three-layer Percoll gradient of 78 %-
69 % and 52 % Percoll, as described previously in the Methods of Manuscript 1 (Boxio et al., 
2004). For this isolation, whole blood was loaded on the 3 step-gradient without using dextran 
sedimentation of RBC for the platelet removal. EDTA 15 mM was used since blood clotting 
is leading to platelet activation and potential binding to leukocytes. Neutrophils were 
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collected at the 78-66 % interface (Figure 2) in tubes coated with 1 % BSA in order to avoid 
their loss on the walls (Bedner et al., 1997). The obtained neutrophils were not activated and 
>95 % pure.  
The limitation of this method was the low yield of 150-350’000 neutrophils/ml blood. Still, 
these granulocytes were used to verify the results obtained with granulocytes derived from 
immortalized bone marrow cells. 
 
Big pellet of RBC
RBC + neutrophils
RBC + lymphocyte
+ monocytes
Buffer
 
Figure 2: Isolation of neutrophils on a three-step Percoll gradient. 
 
Method 3: 
We finally found a way to obtain a high number of granulocytes and monocytes by culturing 
and cloning immortalized mouse bone marrow cells (Sykes and Kamps, 2001) as described 
previously in the Methods of Manuscript 1. The yield of granulocytes isolated on a Percoll 
gradient of 150-350’000 granulocytes/ml blood was indeed too low to permit us to use these 
cells for all settings and experiments. Moreover, the cloning procedure gave the advantage to 
obtain also monocytes in a high number. 
Briefly, the cell lines were established by conditional immortalization of primary murine 
marrow progenitors. For this, the construct E2a/Pbx1, a fusion protein that blocks myeloid 
differentiation in mouse marrow in culture was subcloned into the murine stem cell virus 
(MSCV) retroviral vector used for immortalization. The expression of this fusion protein was 
under the control of the hormone binding domain of the estrogen receptor. Uninfected 
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primary mouse marrow cells differentiate into short-lived granulocytes and monocytes. 
Expression of E2a/Pbx1 immortalizes GM-CSF-dependent myeloid progenitors in the 
presence of estradiol in the culture medium. In the absence of estradiol, the cells differentiate 
in granulocytes (80 %) and monocytes (20 %). 
After a cloning procedure, granulocytic and monocytic progenitors were selected for both wt 
and L-sel-/- mice. Differentiated granulocytes and monocytes were tested for Gr-1 expression, 
a granulocytic marker (Figure 3 A and B) and F4/80 expression, a monocytic marker (Figure 
3 C and D). 
Interestingly, monocytes coming from Lsel-/- mice were difficult to obtain. The percentage of 
cells differentiating in monocytes was clearly below 20 % and they were growing more 
slowly than wt monocytes. Moreover, we were not able to keep them for more than 20 
passages in culture. 
To control whether granulocytes were in a non activated state, 10-7M of PMA was added, a 
known activator of granulocytes, for 10 min at 37°C. The activation of granulocytes was 
expressed as a function of L-selectin shedding and Mac-1 up-regulation, both markers for 
granulocytes activation (Crockett-Torabi et al., 1995). The obtained cells were in a non 
activated state (figure 3 E and F). 
 
Conclusion:  
Studying the role of murine innate immune cells in inflammation processes is expensive and 
time-consuming. Indeed, monocytes and granulocytes are non-mitotic cells and they need to 
be derived from large numbers of mice (Methods 1 and 2) so that their role can be studied in 
wt and Lsel-/- mouse models. By the help of the Method 3, unlimited quantities of functional 
monocytes and granulocytes from wt and Lsel-/- mice were produced. 
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Figure 3: Characterization of granulocytes and monocytes derived from clones of immortalized bone marrow 
cells. Granulocytes (A) and monocytes (B) were stained with Gr-1 and analysed by flow cytometry. Filled area 
represents the Gr-1 staining of progenitor cells.  
Granulocytes (C) and monocytes (D) were stained with F4/80. Filled area represents granulocytes (C) or 
monocytes (D) stained with the secondary Ab only.  
Granulocytes were stained with MEL-14 (E) and Mac-1 (F) before and after activation by PMA. Thin lines 
represent the staining before activation while dashed lines represent the staining after PMA activation. Filled 
area represents the staining with a secondary Ab. 
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Activation of granulocytes by tumor cells 
 
The direct activation of granulocytes in the presence of tumor cells was studied since 
leukocytes were playing a central role in tumor cell transmigration (see Manuscript 1). To test 
this, tumor cells and granulocytes were incubated at different ratios (one part of tumor cells 
for one part or eight parts of granulocytes) and incubated for 4 hours at 37°C. 
Activation of granulocytes is characterized by an up-regulation of the Mac-1 cell surface 
marker and by the shedding of L-selectin molecule (Crockett-Torabi et al., 1995). 
Surprisingly, granulocytes were not activated after this incubation in the presence of tumor 
cells. Indeed, they did not over-express Mac-1 and granulocytes coming from wt mice did not 
shed L-selectin (Figure 4).  
The activation state of granulocytes found in the lower well after 16h of transendothelial 
migration in our assay was tested, and again, no sign of granulocyte activation was detected 
(data not shown). It could be that the time frame studied was not the right one. Most probably, 
endothelial cells may be a pre-requisite for granulocytes to be activated. 
 
A 
 
 
B 
 
 
C 
 
 
 
Figure 4: Activation of granulocytes by tumor cells. The figures A and B present Mac-1 expression at the 
surface of granulocytes coming from wt (A) or L-sel-/- mice (B) after 4h incubation at 37°C in the presence of 
tumor cells. The figure C presents MEL-14 staining of granulocytes coming from wt mice. Filled areas represent 
the staining of granulocytes incubated alone. Dotted lines represent granulocytes incubated in the presence of 
tumor cells at the ratio tumor cells : granulocytes = 1:1, while bold lines represent granulocytes after co-culture 
at the ratio 1:8. Dashed lines represent granulocytes after PMA activation.  
 
71 
 
Adhesion of tumor cells on endothelial cells in the presence of leukocytes 
 
The adhesion of tumor cells to endothelium in the presence of leukocytes was tested. The 
establishment of new contacts between the tumor cell surface and endothelium is required for 
tumor cell invasion. 
MC-38 cells adhere specifically on endothelial cells after 2-3 hours. Adhesion of MC-38 to 
endothelial cells (EC) was tested in the presence or absence of granulocytes for 3 h (Figure 
5A). There was no apparent difference in the number of adherent tumor cells MC-38 on a 
confluent layer of EC irrespective of granulocytes -coming from either wt or Lsel -/- mice- 
(Figure 5B). The adhesion of tumor cells on endothelial cells was L-selectin independent. 
Moreover, we further showed that the granulocytes interacted with MC-38 cells in an L-
selectin independent manner. This was confirmed by the analysis of leukocyte aggregates on 
tumor cells by cytospin (data not shown). 
The promotion of tumor cell migration through endothelium in the presence of granulocytes 
(Figure 2 of Manuscript 1) is not correlated with an enhanced adhesion of tumor cells on 
endothelium. Another possibility is that the adhesion of tumor cells to endothelium in the 
presence of granulocytes may be flow and shear dependent, a well-known phenomenon for L-
selectin molecules (Jadhav et al., 2001; Jadhav and Konstantopoulos, 2002). A further 
explanation could be that the adhesion of MC-38 to endothelium is not L- but P-selectin 
dependent. 
A 
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Figure 5: Adhesion of tumor cells to endothelial cells in the presence of granulocytes. A The pictures show the 
adhesion of MC-38GFP (green) on the EC layer stained with CD31 (red) in the presence / absence of 
granulocytes stained with Gr-1 (white). B The figure is a summary of two representative experiments (40x, 20 
view fields). There was no statistical difference. Columns, mean; bars, SEM. 
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Migration of tumor cells through EC under a FCS gradient 
 
We made the same transendothelial migration assay as described in the Manuscript 1 with the 
only difference that tumor cells were migrating towards a FCS gradient. The medium in the 
upper well was containing 0 % FCS whereas the medium in the lower well was containing 10 
% FCS. Cells were mixed at the following ratios: for one part of tumor cells (20’000), ten 
parts of granulocytes (200’000) and five parts of monocytes (100’000) were added. 
An enhancement of tumor cell migration in the presence of leukocytes was observed but in an 
L-selectin independent manner (Figure 6), whereas leukocytes transmigrate in an L-selectin 
dependent manner (Figure 7). Interestingly, tumor cells migrate in an L-selectin dependent 
manner only when TCM was present at the bottom well (see Manuscript 1). We suggest that 
the absence of L-selectin dependency in tumor cell transmigration is due to the absence of 
TCM. TCM is a conditioned medium, supernatant of the co-culture of endothelial cells and 
tumor cells. These findings suggest that interaction between endothelial cells and tumor cells 
leads to the release of factors that are primordial for tumor cell migration and that mimic the 
microenvironment. Thus, interaction of tumor cells with endothelial cells seems to be pivotal 
for the extravasation process. Moreover, L-selectin dependent leukocyte transmigration in this 
assay can be explained by an L-selectin local activation of the endothelial cells. 
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Figure 6: Migration of tumor cells after 16h transmigration through EC in the presence of a FCS gradient. This 
figure is a summary of at least six independent experiments. Migration of the tumor cells alone was normalized 
at 10 cells.  
 
 
0
25000
50000
75000
**
Tumor cells + + + +
Granulocytes + + + -
Monocytes - - + +
wt
Lsel-/-
*
nu
m
be
r 
of
 m
ig
ra
te
d
le
uk
oc
yt
es
 
Figure 7: Migration of leukocytes accompanying tumor cell transmigration in the presence of a FCS gradient. 
This figure is a summary of at least three independent experiments. ** P<0.0001 
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Section III: Discussion 
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During carcinoma progression, tumor cells express altered glycosylation structures which are 
ligands for selectins. Metastasis is facilitated by the formation of a tumor cell embolus, 
consisting of L-selectin expressing leukocytes and P-selectin expressing platelets aggregated 
around tumor cells. Carcinomas carrying sLex structures can potentially bind L- and P-
selectins. Platelets were shown to be active players in the metastatic spread and protect tumor 
cells from the clearance by innate immune cells (Borsig et al., 2001a; Garcia et al., 2007; 
Nieswandt et al., 1999). The attenuation of metastasis in mice deficient for L-selectin directly 
implicated leukocytes as facilitators of metastasis. However the nature and function of 
leukocytes in the tumor cell emboli remained to be elucidated. 
Leukocytes were shown to be associated with tumor cells trapped in lungs (Läubli et al., 
2006). In this work we have shown that the presence of innate immune cells (granulocytes, 
macrophages) around tumor cells was reduced in the lungs of mice deficient for L-selectin 
(see Manuscript 1). This finding indicates that cell-cell contacts between tumor cells and 
innate immune cells have a pivotal role for the contribution of metastasis. The association 
between tumor cell and innate immune cells has already been correlated with an enhancement 
of metastasis (Coussens et al., 2000; Queen et al., 2005). In a model of breast cancer, 
neutrophils were potential promoters of tumor progression in vivo (Queen et al., 2005). 
Neutrophil infiltration into tumor tissue led to the acquisition of a metastatic phenotype for 
benign murine fibrosarcoma cells (Tazawa et al., 2003). Depletion of tissue-associated 
macrophages by clodronate liposomes resulted in an inhibition of tumor growth (Zeisberger et 
al., 2006). Interestingly, the presence of bone marrow-derived cells modulated skin 
carcinogenesis (Coussens et al., 2000). An increase of metastasis was correlated with an 
enhanced infiltration of macrophages into the primary tumor (Lin et al., 2001). Macrophages 
recruited to the site of primary tumor are able to increase the metastatic potential of tumor 
cells for the colonization of distant sites. The presence of tumor-associated macrophages and 
neutrophils correlates with an increase of metastasis. Innate immune cells in the vicinity of 
tumor cells seem to be decisive for their further outcome. Little is known on the role of 
circulating monocytes associated with tumor cells. In our model, macrophages, granulocytes 
and monocytes associated with tumor cells may have a function important for the 
establishment of metastasis.  
Granulocytes / monocytes promoted tumor cell transmigration through endothelium (see 
Manuscript 1), suggesting that leukocytes associated with tumor cells can increase migratory 
capacities of tumor cells in the blood vessel at the site of extravasation. Neutrophils were 
enhancing the in vitro invasive and in vivo metastatic potential of rat mammary 
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adenocarcinoma cells, by facilitating invasion into basement membrane (Welch et al., 1989). 
The observed facilitation of tumor cell transmigration through endothelium implicated L-
selectin on leukocytes (see Manuscript 1). L-selectin interactions were pivotal for tumor cell 
migration through endothelium. In another study, L-selectin was transfected in carcinoma 
cells in which metastasis was infrequent and mostly localized in the liver (Qian et al., 2001). 
This L-selectin expression induced metastasis to lymph nodes where ligands for L-selectin, 
the adressins are expressed, showing the role of this cell-adhesion molecule in tumor spread. 
L-selectin ligands on the endothelium could be involved in MC-38 tumor cell extravasation. 
In order to further understand the underlying mechanism affecting tumor cell transmigration, 
it would be of interest to characterize the cells expressing L-selectin ligands and partners of 
leukocytes in tumor progression. Even though MC-38 and endothelial cells express L-selectin 
ligands (Läubli et al., 2006) it is still unknown whether tumor or endothelial cells interact 
with leukocytes for the observed facilitation of tumor cell extravasation. One possibility 
would be that leukocytes interact with the endothelium through L-selectin-PSGL-1 
interactions and with tumor cells indirectly through binding with platelets. This would 
implicate a binding through endogenous ligands of endothelium. Studies using inhibition of 
selectins by single-dose heparin suggest that L-selectin on leukocytes may operate later as P-
selectin on platelets during the metastatic cascade (Borsig et al., 2002). Leukocytes may be 
recruited by activated endothelium expressing new L-selectin ligands at the site where tumor 
cells are entrapped in the vasculature. Indeed L-selectin ligands can be induced on the 
endothelium during inflammation (Berg et al., 1998). Leukocytes have a high capability to go 
through endothelium during inflammation and L-selectin can modulate events downstream of 
leukocyte rolling and adhesion (Hickey et al., 2000). The signaling pathway induced by L-
selectin on leukocytes involves an induced expression of TNF-α and IL-8 (Laudanna et al., 
1994). This release of chemokines could modulate the microenvironment of the tumor emboli 
by increasing the survival of tumor cells and /or contribute to their subsequent extravasation 
into tissues.  
In contrast to leukocytes that transmigrate through endothelial cells without disrupting them, 
many tumor cells induce endothelial cell retraction, and in some cases apoptosis or necrosis 
(Honn et al., 1994; Lee et al., 2003). It has been shown in vitro that the underlying endothelial 
cells retracted in contact with MC-38 tumor cells and leukocytes. These observations were 
successfully confirmed also in vivo. An enhancement of endothelial cell permeability was 
observed in presence of tumor cells and L-selectin on leukocytes. Human breast 
adenocarcinoma cells and Lewis lung cancer cells caused retraction of the endothelium (Honn 
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et al., 1994; Uchide et al., 2007). Vascular Endothelial Growth Factor (VEGF) produced by 
breast tumor cells induced endothelial cell retraction and redistribution of actin resulting in 
formation of stress fibers (Lee et al., 2003). Chemokine receptor CXCR4 and its ligand 
stromal cell derived factor 1 α (SDF-1α) were involved in this process (Lee et al., 2004). 
Tumor cells even induce apoptosis of endothelial cells and implicate a specific tumor-
endothelial cell contact-dependent response (Heyder et al., 2002; Kebers et al., 1998). In our 
model, MC-38 in presence of leukocytes and endothelial cells could express chemokines or 
reactive oxygen species able to provoke endothelial cell retraction. Depletion of circulating 
monocytes led to an attenuation of metastasis (see Manuscript 1), meaning that circulatory 
monocytes are pivotal partners for the facilitation of tumor cell metastasis. L-selectin is 
implicated in monocyte activation by tumor cells (Putz and Mannel, 1996).This finding 
confirms that the observed tumor associated circulating monocytes have an important 
function in vivo. Taken together, recruited circulating monocytes may facilitate tumor 
progression by increasing the migratory capacities and /or survival of tumor cells and by 
acting on the permeability of the endothelial cells. 
These findings open a way for new therapies of cancer metastasis. Leukocytes were recruited 
and have been shown to have a major role to promote metastasis. Therefore a treatment 
impairing the recruitment of inflammatory cells by tumor cells and their cell-cell contact 
could lead to reduction of metastasis. The limitation of such therapy is that it could affect the 
physiological role of leukocytes and platelets. It has been shown that a daily ingestion of 
aspirin reduces by half the risk of sporadic colon cancer (Dubois, 2000). Clinical studies 
report that inhibition of chronic inflammation by nonsteroidal anti-inflammatory drugs 
(NSAIDs), particularly COX-2 inhibitors could lead to an impairment of recruitment and 
function of inflammatory cells thereby an attenuation of metastasis (Fosslien, 2000; Pham-
Nguyen et al., 1999). Finally, the targeting of the ligands of selectins could help to limit 
metastasis through blood vessels by inhibiting multiple interactions between tumor cells and 
selectin-bearing platelets, endothelium, and leukocytes. The injection of soluble form of E-
selectin impaired lung metastasis in mice by interfering with the binding of colon carcinoma 
cells to endothelium (Mannori et al., 1997). Further, the blocking of sLex at the surface of 
tumor cells led to reduced metastatic properties of these cells (Fuster et al., 2003). 
Interestingly, heparin bound efficiently P- and L-selectin and inhibited their binding to sLex at 
the concentration used for anticoagulation (Koenig et al., 1998). Heparin treatment is often 
used as anticoagulant treatment for cancer patients suffering from associated thromboembolic 
complications (Smorenburg and Van Noorden, 2001) and beneficial effects of heparin or low-
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molecular-weight heparin on attenuation of metastasis in humans were seen in clinical trials 
(Cosgrove et al., 2002). Studies in mouse models showed that the effect of heparin was not 
only based on its anticoagulant activity (Smorenburg and Van Noorden, 2001). A single dose 
of heparin led to a reduction of platelet-tumor cell aggregate formation in the lung vasculature 
that lasted for some hours and to a reduction of metastasis (Borsig et al., 2001a; Borsig et al., 
2002). Use of low weight heparin in mouse models showed that heparin has an effect on 
attenuation of metastasis by targeting P- and L-selectin (Hostettler et al., 2007). Heparin 
should be injected when tumor cells are still in the vasculature for a therapy through its 
contribution to selectin inhibition. Heparin therapy through selectin inhibition and cell-cell 
interaction could be beneficial for cancer patients for treatment of metastatic progression. 
Many evidences in mouse show that L-selectin on leukocytes promotes hematogenous 
metastasis. The contact between these immune cells with tumor cells and endothelial cells 
exerts a pivotal role for cancer progression. Inhibition of metastasis by impairment of immune 
cell recruitment by NSAIDs in human confirms the observations derived from the mouse 
model. Targeting the recruitment of inflammatory cells or the binding between tumor cells 
and inflammatory cells by inhibiting selectin interactions could prove to be a treatment for a 
metastatic disease.  
 
80 
 
 
Section IV: References 
81 
 
 
Aird, W. C. (2003). Endothelial cell heterogeneity. Crit Care Med 31, S221-230. 
Arbones, M. L., Ord, D. C., Ley, K., Ratech, H., Maynard-Curry, C., Otten, G., Capon, D. J., 
and Tedder, T. F. (1994). Lymphocyte homing and leukocyte rolling and migration are 
impaired in L-selectin-deficient mice. Immunity 1, 247-260. 
Arias, A. M. (2001). Epithelial mesenchymal interactions in cancer and development. Cell 
105, 425-431. 
Balkwill, F. (2004). Cancer and the chemokine network. Nat Rev Cancer 4, 540-550. 
Balkwill, F., Charles, K. A., and Mantovani, A. (2005). Smoldering and polarized 
inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211-217. 
Balkwill, F., and Mantovani, A. (2001). Inflammation and cancer: back to Virchow? Lancet 
357, 539-545. 
Bedner, E., Burfeind, P., Gorczyca, W., Melamed, M. R., and Darzynkiewicz, Z. (1997). 
Laser scanning cytometry distinguishes lymphocytes, monocytes, and granulocytes by 
differences in their chromatin structure. Cytometry 29, 191-196. 
Berg, E. L., Mullowney, A. T., Andrew, D. P., Goldberg, J. E., and Butcher, E. C. (1998). 
Complexity and differential expression of carbohydrate epitopes associated with L-selectin 
recognition of high endothelial venules. Am J Pathol 152, 469-477. 
Biancone, L., Araki, M., Araki, K., Vassalli, P., and Stamenkovic, I. (1996). Redirection of 
tumor metastasis by expression of E-selectin in vivo. J Exp Med 183, 581-587. 
Bingle, L., Brown, N. J., and Lewis, C. E. (2002). The role of tumour-associated macrophages 
in tumour progression: implications for new anticancer therapies. J Pathol 196, 254-265. 
Borsig, L. (2004). Selectins facilitate carcinoma metastasis and heparin can prevent them. 
News Physiol Sci 19, 16-21. 
Borsig, L., Wong, R., Feramisco, J., Nadeau, D. R., Varki, N. M., and Varki, A. (2001a). 
Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, 
carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A 98, 3352-3357. 
Borsig, L., Wong, R., Feramisco, J., Nadeau, D. R., Varki, N. M., and Varki, A. (2001b). 
Pictures in Molecular Medicine: Three-dimensional visualization of intravascular tumor cells 
in mice. Trends MolMed 7, 377. 
Borsig, L., Wong, R., Hynes, R. O., Varki, N. M., and Varki, A. (2002). Synergistic effects of 
L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate 
leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A 99, 2193-2198. 
Boucharaba, A., Serre, C. M., Gres, S., Saulnier-Blache, J. S., Bordet, J. C., Guglielmi, J., 
Clezardin, P., and Peyruchaud, O. (2004). Platelet-derived lysophosphatidic acid supports the 
progression of osteolytic bone metastases in breast cancer. J Clin Invest 114, 1714-1725. 
Boxio, R., Bossenmeyer-Pourie, C., Steinckwich, N., Dournon, C., and Nusse, O. (2004). 
Mouse bone marrow contains large numbers of functionally competent neutrophils. J Leukoc 
Biol 75, 604-611. 
Brockhausen, I. (2006). Mucin-type O-glycans in human colon and breast cancer: 
glycodynamics and functions. EMBO Reports 7, 599-604. 
82 
 
Brown, J. R., Fuster, M. M., Li, R., Varki, N., Glass, C. A., and Esko, J. D. (2006). A 
disaccharide-based inhibitor of glycosylation attenuates metastatic tumor cell dissemination. 
Clin Cancer Res 12, 2894-2901. 
Brown, L. F., Guidi, A. J., Schnitt, S. J., Van De Water, L., Iruela-Arispe, M. L., Yeo, T. K., 
Tognazzi, K., and Dvorak, H. F. (1999). Vascular stroma formation in carcinoma in situ, 
invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 5, 1041-1056. 
Chambers, A. F., Groom, A. C., and MacDonald, I. C. (2002). Dissemination and growth of 
cancer cells in metastatic sites. Nat Rev Cancer 2, 563-572. 
Cosgrove, R. H., Zacharski, L. R., Racine, E., and Andersen, J. C. (2002). Improved cancer 
mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin 
Thromb Hemost 28, 79-88. 
Cotter, M. J., Norman, K. E., Hellewell, P. G., and Ridger, V. C. (2001). A novel method for 
isolation of neutrophils from murine blood using negative immunomagnetic separation. Am J 
Pathol 159, 473-481. 
Coussens, L. M., Tinkle, C. L., Hanahan, D., and Werb, Z. (2000). MMP-9 supplied by bone 
marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490. 
Coussens, L. M., and Werb, Z. (2002). Inflammation and cancer. Nature 420, 860-867. 
Crockett-Torabi, E., Sulenbarger, B., Smith, C. W., and Fantone, J. C. (1995). Activation of 
human neutrophils through L-selectin and Mac-1 molecules. J Immunol 154, 2291-2302. 
de Visser, K. E., Eichten, A., and Coussens, L. M. (2006). Paradoxical roles of the immune 
system during cancer development. Nat Rev Cancer 6, 24-37. 
de Visser, K. E., Korets, L. V., and Coussens, L. M. (2005). De novo carcinogenesis 
promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411-423. 
Dennis, J. W., Pawling, J., Cheung, P., Partridge, E., and Demetriou, M. (2002). UDP-N-
acetylglucosamine:alpha-6-D-mannoside beta1,6 N-acetylglucosaminyltransferase V (Mgat5) 
deficient mice. Biochim Biophys Acta 1573, 414-422. 
Di Carlo, E., Forni, G., Lollini, P., Colombo, M. P., Modesti, A., and Musiani, P. (2001). The 
intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97, 339-345. 
Dolberg, D. S., Hollingsworth, R., Hertle, M., and Bissell, M. J. (1985). Wounding and its 
role in RSV-mediated tumor formation. Science 230, 676-678. 
Dole, V. S., Bergmeier, W., Mitchell, H. A., Eichenberger, S. C., and Wagner, D. D. (2005). 
Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of 
P-selectin. Blood 106, 2334-2339. 
Dubois, R. N. (2000). Review article: cyclooxygenase--a target for colon cancer prevention. 
Aliment Pharmacol Ther 14 Suppl 1, 64-67. 
Dunn, G. P., Old, L. J., and Schreiber, R. D. (2004). The immunobiology of cancer 
immunosurveillance and immunoediting. Immunity 21, 137-148. 
Dvorak, H. F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma 
generation and wound healing. N Engl J Med 315, 1650-1659. 
Dvorak, H. F., Sioussat, T. M., Brown, L. F., Berse, B., Nagy, J. A., Sotrel, A., Manseau, E. 
J., Van de Water, L., and Senger, D. R. (1991). Distribution of vascular permeability factor 
(vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp 
Med 174, 1275-1278. 
83 
 
Fidler, I. J. (2002). The organ microenvironment and cancer metastasis. Differentiation 70, 
498-505. 
Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis 
revisited. Nat Rev Cancer 3, 453-458. 
Fields, R. C., Osterholzer, J. J., Fuller, J. A., Thomas, E. K., Geraghty, P. J., and Mule, J. J. 
(1998). Comparative analysis of murine dendritic cells derived from spleen and bone marrow. 
J Immunother 21, 323-339. 
Fosslien, E. (2000). Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 
30, 3-21. 
Fuster, M. M., Brown, J. R., Wang, L., and Esko, J. D. (2003). A disaccharide precursor of 
sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res 63, 2775-2781. 
Fuster, M. M., and Esko, J. D. (2005). The sweet and sour of cancer: glycans as novel 
therapeutic targets. Nat Rev Cancer 5, 526-542. 
Garcia, J., Callewaert, N., and Borsig, L. (2007). P-selectin mediates metastatic progression 
through binding to sulfatides on carcinoma cells. Glycobiology 17, 185-196. 
Gasic, G. J. (1984). Role of plasma, platelets, and endothelial cells in tumor metastasis. 
Cancer Metastasis Rev 3, 99-114. 
Glinsky, V. V., Glinsky, G. V., Rittenhouse-Olson, K., Huflejt, M. E., Glinskii, O. V., 
Deutscher, S. L., and Quinn, T. P. (2001). The role of Thomsen-Friedenreich antigen in 
adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 61, 4851-
4857. 
Guo, H. B., Lee, I., Kamar, M., Akiyama, S. K., and Pierce, M. (2002). Aberrant N-
glycosylation of beta1 integrin causes reduced alpha5beta1 integrin clustering and stimulates 
cell migration. Cancer Res 62, 6837-6845. 
Hakomori, S. (1996). Tumor malignancy defined by aberrant glycosylation and 
sphingo(glyco)lipid metabolism. Cancer Res 56, 5309-5318. 
Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70. 
Hayashi, N., Nakamori, S., Okami, J., Nagano, H., Dono, K., Umeshita, K., Sakon, M., 
Narimatsu, H., and Monden, M. (2004). Association between expression levels of CA 19-9 
and N-acetylglucosamine-beta;1,3-galactosyltransferase 5 gene in human pancreatic cancer 
tissue. Pathobiology 71, 26-34. 
Heyder, C., Gloria-Maercker, E., Entschladen, F., Hatzmann, W., Niggemann, B., Zanker, K. 
S., and Dittmar, T. (2002). Realtime visualization of tumor cell/endothelial cell interactions 
during transmigration across the endothelial barrier. J Cancer Res Clin Oncol 128, 533-538. 
Hickey, M. J., Forster, M., Mitchell, D., Kaur, J., De Caigny, C., and Kubes, P. (2000). L-
selectin facilitates emigration and extravascular locomotion of leukocytes during acute 
inflammatory responses in vivo. J Immunol 165, 7164-7170. 
Hiratsuka, S., Nakamura, K., Iwai, S., Murakami, M., Itoh, T., Kijima, H., Shipley, J. M., 
Senior, R. M., and Shibuya, M. (2002). MMP9 induction by vascular endothelial growth 
factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2, 289-300. 
Hirohashi, S., and Kanai, Y. (2003). Cell adhesion system and human cancer morphogenesis. 
Cancer Science 94, 575-581. 
84 
 
Hollingsworth, M. A., and Swanson, B. J. (2004). Mucins in cancer: protection and control of 
the cell surface. Nat Rev Cancer 4, 45-60. 
Honn, K. V., and Tang, D. G. (1992). Adhesion molecules and tumor cell interaction with 
endothelium and subendothelial matrix. Cancer Metastasis Rev 11, 353-375. 
Honn, K. V., Tang, D. G., and Chen, Y. Q. (1992a). Platelets and cancer metastasis: more 
than an epiphenomenon. Semin Thromb Hemost 18, 392-415. 
Honn, K. V., Tang, D. G., and Crissman, J. D. (1992b). Platelets and cancer metastasis: a 
causal relationship? Cancer Metastasis Rev 11, 325-351. 
Honn, K. V., Tang, D. G., Grossi, I., Duniec, Z. M., Timar, J., Renaud, C., Leithauser, M., 
Blair, I., Johnson, C. R., Diglio, C. A., and et al. (1994). Tumor cell-derived 12(S)-
hydroxyeicosatetraenoic acid induces microvascular endothelial cell retraction. Cancer Res 
54, 565-574. 
Hostettler, N., Naggi, A., Torri, G., Ishai-Michaeli, R., Casu, B., Vlodavsky, I., and Borsig, L. 
(2007). P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant 
heparins. FASEB J 21, 3562-3572. 
Im, J. H., Fu, W., Wang, H., Bhatia, S. K., Hammer, D. A., Kowalska, M. A., and Muschel, 
R. J. (2004). Coagulation facilitates tumor cell spreading in the pulmonary vasculature during 
early metastatic colony formation. Cancer Res 64, 8613-8619. 
Inohara, H., Akahani, S., Koths, K., and Raz, A. (1996). Interactions between galectin-3 and 
Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 56, 4530-4534. 
Ito, H., Hiraiwa, N., Sawada-Kasugai, M., Akamatsu, S., Tachikawa, T., Kasai, Y., Akiyama, 
S., Ito, K., Takagi, H., and Kannagi, R. (1997). Altered mRNA expression of specific 
molecular species of fucosyl- and sialyl-transferases in human colorectal cancer tissues. Int J 
Cancer 71, 556-564. 
Izumi, Y., Taniuchi, Y., Tsuji, T., Smith, C. W., Nakamori, S., Fidler, I. J., and Irimura, T. 
(1995). Characterization of human colon carcinoma variant cells selected for sialyl Lex 
carbohydrate antigen: liver colonization and adhesion to vascular endothelial cells. Exp Cell 
Res 216, 215-221. 
Jadhav, S., Bochner, B. S., and Konstantopoulos, K. (2001). Hydrodynamic shear regulates 
the kinetics and receptor specificity of polymorphonuclear leukocyte-colon carcinoma cell 
adhesive interactions. J Immunol 167, 5986-5993. 
Jadhav, S., and Konstantopoulos, K. (2002). Fluid shear- and time-dependent modulation of 
molecular interactions between PMNs and colon carcinomas. Am J Physiol Cell Physiol 283, 
C1133-1143. 
Kakinuma, T., and Hwang, S. T. (2006). Chemokines, chemokine receptors, and cancer 
metastasis. J Leukoc Biol 79, 639-651. 
Kalluri, R. (2003). Basement membranes: structure, assembly and role in tumour 
angiogenesis. Nat Rev Cancer 3, 422-433. 
Kalluri, R., and Zeisberg, M. (2006). Fibroblasts in cancer. Nat Rev Cancer 6, 392-401. 
Kannagi, R., Izawa, M., Koike, T., Miyazaki, K., and Kimura, N. (2004). Carbohydrate-
mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 95, 377-384. 
Kansas, G. S. (1996). Selectins and their ligands: current concepts and controversies. Blood 
88, 3259-3287. 
85 
 
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., 
MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005). VEGFR1-positive 
haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-
827. 
Karin, M. (2006). Nuclear factor-[kappa]B in cancer development and progression. Nature 
441, 431-436. 
Karpatkin, S., and Pearlstein, E. (1981). Role of platelets in tumor cell metastases. Ann Intern 
Med 95, 636-641. 
Karpatkin, S., Pearlstein, E., Ambrogio, C., and Coller, B. S. (1988). Role of adhesive 
proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 
81, 1012-1019. 
Kebers, F., Lewalle, J. M., Desreux, J., Munaut, C., Devy, L., Foidart, J. M., and Noel, A. 
(1998). Induction of endothelial cell apoptosis by solid tumor cells. Exp Cell Res 240, 197-
205. 
Kim, Y. J., Borsig, L., Han, H. L., Varki, N. M., and Varki, A. (1999). Distinct selectin 
ligands on colon carcinoma mucins can mediate pathological interactions among platelets, 
leukocytes, and endothelium. Am J Pathol 155, 461-472. 
Kim, Y. J., Borsig, L., Varki, N. M., and Varki, A. (1998). P-selectin deficiency attenuates 
tumor growth and metastasis. Proc Natl Acad Sci U S A 95, 9325-9330. 
Kim, Y. J., and Varki, A. (1997). Perspectives on the significance of altered glycosylation of 
glycoproteins in cancer. Glycoconj J 14, 569-576. 
Koenig, A., Norgard-Sumnicht, K., Linhardt, R., and Varki, A. (1998). Differential 
interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. 
Implications for the use of unfractionated and low molecular weight heparins as therapeutic 
agents. J Clin Invest 101, 877-889. 
Kojima, N., Handa, K., Newman, W., and Hakomori, S. (1992). Inhibition of selectin-
dependent tumor cell adhesion to endothelial cells and platelets by blocking O-glycosylation 
of these cells. Biochem Biophys Res Commun 182, 1288-1295. 
Korczak, B., Goss, P., Fernandez, B., Baker, M., and Dennis, J. W. (1994). Branching N-
linked oligosaccharides in breast cancer. Adv Exp Med Biol 353, 95-104. 
Kuan, S. F., Byrd, J. C., Basbaum, C., and Kim, Y. S. (1989). Inhibition of mucin 
glycosylation by aryl-N-acetyl-alpha-galactosaminides in human colon cancer cells. J Biol 
Chem 264, 19271-19277. 
Kulbe, H., Thompson, R., Wilson, J. L., Robinson, S., Hagemann, T., Fatah, R., Gould, D., 
Ayhan, A., and Balkwill, F. (2007). The inflammatory cytokine tumor necrosis factor-alpha 
generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer 
Res 67, 585-592. 
Kuperwasser, C., Chavarria, T., Wu, M., Magrane, G., Gray, J. W., Carey, L., Richardson, A., 
and Weinberg, R. A. (2004). Reconstruction of functionally normal and malignant human 
breast tissues in mice. Proc Natl Acad Sci U S A 101, 4966-4971. 
Lafrenie, R. M., Gallo, S., Podor, T. J., Buchanan, M. R., and Orr, F. W. (1994). The relative 
roles of vitronectin receptor, E-selectin and alpha 4 beta 1 in cancer cell adhesion to 
interleukin-1-treated endothelial cells. Eur J Cancer 30A, 2151-2158. 
86 
 
Läubli, H., Stevenson, J. L., Varki, A., Varki, N. M., and Borsig, L. (2006). L-selectin 
facilitation of metastasis involves temporal induction of fut7-dependent ligands at sites of 
tumor cell arrest. Cancer Res 66, 1536-1542. 
Laudanna, C., Constantin, G., Baron, P., Scarpini, E., Scarlato, G., Cabrini, G., Dechecchi, C., 
Rossi, F., Cassatella, M. A., and Berton, G. (1994). Sulfatides trigger increase of cytosolic 
free calcium and enhanced expression of tumor necrosis factor-alpha and interleukin-8 mRNA 
in human neutrophils. Evidence for a role of L-selectin as a signaling molecule. J Biol Chem 
269, 4021-4026. 
Lee, B. C., Lee, T. H., Avraham, S., and Avraham, H. K. (2004). Involvement of the 
chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer 
cell migration through human brain microvascular endothelial cells. Mol Cancer Res 2, 327-
338. 
Lee, T. H., Avraham, H. K., Jiang, S., and Avraham, S. (2003). Vascular endothelial growth 
factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through 
regulation of brain microvascular endothelial cell permeability. J Biol Chem 278, 5277-5284. 
Ley, K. (2002). Integration of inflammatory signals by rolling neutrophils. Immunol Rev 186, 
8-18. 
Lin, E. Y., Gouon-Evans, V., Nguyen, A. V., and Pollard, J. W. (2002). The Macrophage 
Growth Factor CSF-1 in Mammary Gland Development and Tumor Progression. J Mammary 
Gland Biol Neoplasia 7, 147-162. 
Lin, E. Y., Li, J.-F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D. A., Qian, H., Xue, X.-n., 
and Pollard, J. W. (2006). Macrophages Regulate the Angiogenic Switch in a Mouse Model 
of Breast Cancer. Cancer Res 66, 11238-11246. 
Lin, E. Y., Nguyen, A. V., Russell, R. G., and Pollard, J. W. (2001). Colony-stimulating 
factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193, 727-740. 
Liotta, L. A., and Kohn, E. C. (2001). The microenvironment of the tumour-host interface. 
Nature 411, 375-379. 
Lowe, J. B. (2003). Glycan-dependent leukocyte adhesion and recruitment in inflammation. 
Curr Opin Cell Biol 15, 531-538. 
Lu, Y., Cai, Z., Xiao, G., Keller, E. T., Mizokami, A., Yao, Z., Roodman, G. D., and Zhang, 
J. (2007). Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. 
Cancer Res 67, 3646-3653. 
Ludwig, R. J., Boehme, B., Podda, M., Henschler, R., Jager, E., Tandi, C., Boehncke, W. H., 
Zollner, T. M., Kaufmann, R., and Gille, J. (2004). Endothelial P-selectin as a target of 
heparin action in experimental melanoma lung metastasis. Cancer Res 64, 2743-2750. 
Luo, J.-L., Tan, W., Ricono, J. M., Korchynskyi, O., Zhang, M., Gonias, S. L., Cheresh, D. 
A., and Karin, M. (2007). Nuclear cytokine-activated IKKα controls prostate cancer 
metastasis by repressing Maspin. Nature 446, 690-694. 
Maier, T., Holda, J. H., and Claman, H. N. (1989). Natural suppressor cells. Prog Clin Biol 
Res 288, 235-244. 
Majuri, M. L., Niemela, R., Tiisala, S., Renkonen, O., and Renkonen, R. (1995). Expression 
and function of alpha 2,3-sialyl- and alpha 1,3/1,4-fucosyltransferases in colon 
adenocarcinoma cell lines: role in synthesis of E-selectin counter-receptors. Int J Cancer 63, 
551-559. 
87 
 
Mannori, G., Crottet, P., Cecconi, O., Hanasaki, K., Aruffo, A., Nelson, R. M., Varki, A., and 
Bevilacqua, M. P. (1995). Differential colon cancer cell adhesion to E-, P-, and L-selectin: 
role of mucin-type glycoproteins. Cancer Res 55, 4425-4431. 
Mannori, G., Santoro, D., Carter, L., Corless, C., Nelson, R. M., and Bevilacqua, M. P. 
(1997). Inhibition of colon carcinoma cell lung colony formation by a soluble form of E-
selectin. Am J Pathol 151, 233-243. 
Mantovani, A., Bottazzi, B., Colotta, F., Sozzani, S., and Ruco, L. (1992). The origin and 
function of tumor-associated macrophages. Immunol Today 13, 265-270. 
Marelli-Berg, F. M., Peek, E., Lidington, E. A., Stauss, H. J., and Lechler, R. I. (2000). 
Isolation of endothelial cells from murine tissue. J Immunol Methods 244, 205-215. 
McEver, R. P. (2002). Selectins: lectins that initiate cell adhesion under flow. Curr Opin Cell 
Biol 14, 581-586. 
Melani, C., Chiodoni, C., Forni, G., and Colombo, M. P. (2003). Myeloid cell expansion 
elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic 
BALB/c mice suppresses immune reactivity. Blood 102, 2138-2145. 
Moore, R. J., Owens, D. M., Stamp, G., Arnott, C., Burke, F., East, N., Holdsworth, H., 
Turner, L., Rollins, B., Pasparakis, M., et al. (1999). Mice deficient in tumor necrosis factor-
[alpha] are resistant to skin carcinogenesis. Nat Med 5, 828-831. 
Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., 
Murphy, E., Yuan, W., Wagner, S. N., et al. (2001). Involvement of chemokine receptors in 
breast cancer metastasis. Nature 410, 50-56. 
Nakamori, S., Kameyama, M., Imaoka, S., Furukawa, H., Ishikawa, O., Sasaki, Y., Kabuto, 
T., Iwanaga, T., Matsushita, Y., and Irimura, T. (1993). Increased expression of sialyl Lewisx 
antigen correlates with poor survival in patients with colorectal carcinoma: 
clinicopathological and immunohistochemical study. Cancer Res 53, 3632-3637. 
Nash, G. F., Turner, L. F., Scully, M. F., and Kakkar, A. K. (2002). Platelets and cancer. 
Lancet Oncol 3, 425-430. 
Negus, R. P., Stamp, G. W., Hadley, J., and Balkwill, F. R. (1997). Quantitative assessment of 
the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C 
chemokines. Am J Pathol 150, 1723-1734. 
Nierodzik, M. L., and Karpatkin, S. (2006). Thrombin induces tumor growth, metastasis, and 
angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10, 
355-362. 
Nieswandt, B., Hafner, M., Echtenacher, B., and Mannel, D. N. (1999). Lysis of tumor cells 
by natural killer cells in mice is impeded by platelets. Cancer Res 59, 1295-1300. 
Nozawa, H., Chiu, C., and Hanahan, D. (2006). Infiltrating neutrophils mediate the initial 
angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 
103, 12493-12498. 
Orr, F. W., Wang, H. H., Lafrenie, R. M., Scherbarth, S., and Nance, D. M. (2000). 
Interactions between cancer cells and the endothelium in metastasis. J Pathol 190, 310-329. 
Orr, F. W., and Warner, D. J. (1990). Effects of systemic complement activation and 
neutrophil-mediated pulmonary injury on the retention and metastasis of circulating cancer 
cells in mouse lungs. Lab Invest 62, 331-338. 
88 
 
Paget, S. (1889). The distribution of secondary growths in cancer of the breast. The Lancet 
133, 571-573. 
Palumbo, J. S., Talmage, K. E., Massari, J. V., La Jeunesse, C. M., Flick, M. J., Kombrinck, 
K. W., Jirouskova, M., and Degen, J. L. (2005). Platelets and fibrin(ogen) increase metastatic 
potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105, 178-
185. 
Pham-Nguyen, K. B., Yang, W., Saxena, R., Thung, S. N., Woo, S. L., and Chen, S. H. 
(1999). Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon 
carcinoma. Int J Cancer 81, 813-819. 
Piller, F., Cartron, J. P., and Tuppy, H. (1980). Increase of blood group A and loss of blood 
group Sda activity in the mucus from human neoplastic colon. Revue Francaise de 
Transfusion et Immuno-Hematologie 23, 599-611. 
Poggi, A., Stella, M., and Donati, M. B. (1993). The importance of blood cell-vessel wall 
interactions in tumour metastasis. Baillieres Clinical Haematology 6, 731-752. 
Pollard, J. W. (2004). Tumour-educated macrophages promote tumour progression and 
metastasis. Nat Rev Cancer 4, 71-78. 
Poon, R. T., Ng, I. O., Lau, C., Zhu, L. X., Yu, W. C., Lo, C. M., Fan, S. T., and Wong, J. 
(2001). Serum vascular endothelial growth factor predicts venous invasion in hepatocellular 
carcinoma: a prospective study. Ann Surg 233, 227-235. 
Putz, E. F., and Mannel, D. N. (1996). A role for L-selectin in monocyte activation by Jurkat 
tumour cells. Scand J Immunol 44, 556-564. 
Qian, F., Hanahan, D., and Weissman, I. L. (2001). L-selectin can facilitate metastasis to 
lymph nodes in a transgenic mouse model of carcinogenesis. Proc Natl Acad Sci U S A 98, 
3976-3981. 
Queen, M. M., Ryan, R. E., Holzer, R. G., Keller-Peck, C. R., and Jorcyk, C. L. (2005). 
Breast Cancer Cells Stimulate Neutrophils to Produce Oncostatin M: Potential Implications 
for Tumor Progression. Cancer Res 65, 8896-8904. 
Reutershan, J., Morris, M. A., Burcin, T. L., Smith, D. F., Chang, D., Saprito, M. S., and Ley, 
K. (2006). Critical role of endothelial CXCR2 in LPS-induced neutrophil migration into the 
lung. J Clin Invest 116, 695-702. 
Rhodes, J. M., and Campbell, B. J. (2002). Inflammation and colorectal cancer: IBD-
associated and sporadic cancer compared. Trends MolMed 8, 10-16. 
Ronnov-Jessen, L., Petersen, O. W., and Bissell, M. J. (1996). Cellular changes involved in 
conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76, 
69-125. 
Rosen, S. D. (2004). Ligands for L-selectin: homing, inflammation, and beyond. Annu Rev 
Immunol 22, 129-156. 
Saio, M., Radoja, S., Marino, M., and Frey, A. B. (2001). Tumor-infiltrating macrophages 
induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and 
mediated by both the cell-associated form of TNF and nitric oxide. J Immunol 167, 5583-
5593. 
Sandel, M. H., Dadabayev, A. R., Menon, A. G., Morreau, H., Melief, C. J., Offringa, R., van 
der Burg, S. H., Janssen-van Rhijn, C. M., Ensink, N. G., Tollenaar, R. A., et al. (2005). 
89 
 
Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation 
status and intratumoral localization. Clin Cancer Res 11, 2576-2582. 
Schadendorf, D., Heidel, J., Gawlik, C., Suter, L., and Czarnetzki, B. M. (1995). Association 
with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as 
well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst 87, 366-371. 
Schioppa, T., Uranchimeg, B., Saccani, A., Biswas, S. K., Doni, A., Rapisarda, A., 
Bernasconi, S., Saccani, S., Nebuloni, M., Vago, L., et al. (2003). Regulation of the 
chemokine receptor CXCR4 by hypoxia. J Exp Med 198, 1391-1402. 
Scotton, C. J., Wilson, J. L., Scott, K., Stamp, G., Wilbanks, G. D., Fricker, S., Bridger, G., 
and Balkwill, F. R. (2002). Multiple Actions of the Chemokine CXCL12 on Epithelial Tumor 
Cells in Human Ovarian Cancer. Cancer Res 62, 5930-5938. 
Serafini, P., De Santo, C., Marigo, I., Cingarlini, S., Dolcetti, L., Gallina, G., Zanovello, P., 
and Bronte, V. (2004). Derangement of immune responses by myeloid suppressor cells. 
Cancer Immunol Immunother 53, 64-72. 
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., 
Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999). Antitumor Activity of Thalidomide in 
Refractory Multiple Myeloma. N Engl J Med 341, 1565-1571. 
Sitia, G., Isogawa, M., Kakimi, K., Wieland, S. F., Chisari, F. V., and Guidotti, L. G. (2002). 
Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver 
without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. 
Proc Natl Acad Sci U S A 99, 13717-13722. 
Smorenburg, S. M., and Van Noorden, C. J. (2001). The complex effects of heparins on 
cancer progression and metastasis in experimental studies. Pharmacol Rev 53, 93-105. 
Sperandio, M., Smith, M. L., Forlow, S. B., Olson, T. S., Xia, L., McEver, R. P., and Ley, K. 
(2003). P-selectin Glycoprotein Ligand-1 Mediates L-Selectin-dependent Leukocyte Rolling 
in Venules. J Exp Med 197, 1355-1363. 
Sporn, M. B. (1996). The war on cancer.[see comment]. Lancet 347, 1377-1381. 
Steinbach, F., Tanabe, K., Alexander, J., Edinger, M., Tubbs, R., Brenner, W., Stockle, M., 
Novick, A. C., and Klein, E. A. (1996). The influence of cytokines on the adhesion of renal 
cancer cells to endothelium. J Urol 155, 743-748. 
Stockton, R. A., Schaefer, E., and Schwartz, M. A. (2004). p21-activated kinase regulates 
endothelial permeability through modulation of contractility. J Biol Chem 279, 46621-46630. 
Subiza, J. L., Vinuela, J. E., Rodriguez, R., Gil, J., Figueredo, M. A., and De La Concha, E. 
G. (1989). Development of splenic natural suppressor (NS) cells in Ehrlich tumor-bearing 
mice. Int J Cancer 44, 307-314. 
Sykes, D. B., and Kamps, M. P. (2001). Estrogen-dependent E2a/Pbx1 myeloid cell lines 
exhibit conditional differentiation that can be arrested by other leukemic oncoproteins. Blood 
98, 2308-2318. 
Taylor, M. E., and Drickamer, K. (2006). Introduction to Glycobiology: Oxford University 
Press). 
Tazawa, H., Okada, F., Kobayashi, T., Tada, M., Mori, Y., Une, Y., Sendo, F., Kobayashi, 
M., and Hosokawa, M. (2003). Infiltration of neutrophils is required for acquisition of 
metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-
associated carcinogenesis and tumor progression. Am J Pathol 163, 2221-2232. 
90 
 
Tedder, T. F., Steeber, D. A., and Pizcueta, P. (1995). L-selectin-deficient mice have impaired 
leukocyte recruitment into inflammatory sites. J Exp Med 181, 2259-2264. 
Tiruppathi, C., Freichel, M., Vogel, S. M., Paria, B. C., Mehta, D., Flockerzi, V., and Malik, 
A. B. (2002). Impairment of store-operated Ca2+ entry in TRPC4(-/-) mice interferes with 
increase in lung microvascular permeability.[see comment]. Circ Res 91, 70-76. 
Uchide, K., Sakon, M., Ariyoshi, H., Nakamori, S., Tokunaga, M., and Monden, M. (2007). 
Cancer cells cause vascular endothelial cell (vEC) retraction via 12(S)HETE secretion; the 
possible role of cancer cell derived microparticle. Ann Surg Oncol 14, 862-868. 
Varki, A., Cummings, R. D., Esko, J. D., Freeze, H., Hart, G., and Marth, J. D. (1999). 
Essentials of Glycobiology,  (New York: Cold Spring Harbor Laboratory Press). 
Wang, H., Fu, W., Im, J. H., Zhou, Z., Santoro, S. A., Iyer, V., DiPersio, C. M., Yu, Q. C., 
Quaranta, V., Al-Mehdi, A., and Muschel, R. J. (2004). Tumor cell {alpha}3{beta}1 integrin 
and vascular laminin-5 mediate pulmonary arrest and metastasis. J Cell Biol 164, 935-941. 
Wang, L., Fuster, M., Sriramarao, P., and Esko, J. D. (2005). Endothelial heparan sulfate 
deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during 
inflammatory responses. Nat Immunol 6, 902-910. 
Weinberg, R. A. (2007). The Biology of Cancer,  (New York: Garland Science, Taylor and 
Francis Group, LLC). 
Weis, S., Cui, J., Barnes, L., and Cheresh, D. (2004). Endothelial barrier disruption by VEGF-
mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 167, 
223-229. 
Weis, W. I., and Drickamer, K. (1996). Structural Basis of Lectin-Carbohydrate Recognition. 
Annu Rev Biochem 65, 441-473. 
Welch, D. R., Schissel, D. J., Howrey, R. P., and Aeed, P. A. (1989). Tumor-elicited 
polymorphonuclear cells, in contrast to "normal" circulating polymorphonuclear cells, 
stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells. Proc Natl 
Acad Sci U S A 86, 5859-5863. 
Wong, C. W., Song, C., Grimes, M. M., Fu, W., Dewhirst, M. W., Muschel, R. J., and Al-
Mehdi, A. B. (2002). Intravascular location of breast cancer cells after spontaneous metastasis 
to the lung. Am J Pathol 161, 749-753. 
Worthylake, R. A., and Burridge, K. (2001). Leukocyte transendothelial migration: 
orchestrating the underlying molecular machinery. Curr Opin Cell Biol 13, 569-577. 
Wu, Q. D., Wang, J. H., Condron, C., Bouchier-Hayes, D., and Redmond, H. P. (2001). 
Human neutrophils facilitate tumor cell transendothelial migration. Am J Physiol Cell Physiol 
280, C814-C822. 
Wyckoff, J. B., Wang, Y., Lin, E. Y., Li, J. F., Goswami, S., Stanley, E. R., Segall, J. E., 
Pollard, J. W., and Condeelis, J. (2007). Direct visualization of macrophage-assisted tumor 
cell intravasation in mammary tumors. Cancer Res 67, 2649-2656. 
Ye, C., Kiriyama, K., Mistuoka, C., Kannagi, R., Ito, K., Watanabe, T., Kondo, K., Akiyama, 
S., and Takagi, H. (1995). Expression of E-selectin on endothelial cells of small veins in 
human colorectal cancer. Int J Cancer 61, 455-460. 
Yoshimura, M., Ihara, Y., Matsuzawa, Y., and Taniguchi, N. (1996). Aberrant glycosylation 
of E-cadherin enhances cell-cell binding to suppress metastasis. J Biol Chem 271, 13811-
13815. 
91 
 
Zarbock, A., Singbartl, K., and Ley, K. (2006). Complete reversal of acid-induced acute lung 
injury by blocking of platelet-neutrophil aggregation. J Clin Invest 116, 3211-3219. 
Zeisberger, S. M., Odermatt, B., Marty, C., Zehnder-Fjallman, A. H., Ballmer-Hofer, K., and 
Schwendener, R. A. (2006). Clodronate-liposome-mediated depletion of tumour-associated 
macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 95, 
272-281. 
Zhang, K., Baeckstrom, D., and Hansson, G. C. (1994). A secreted mucin carrying sialyl-
Lewis a from colon carcinoma cells binds to E-selectin and inhibits HL-60 cell adhesion. Int J 
Cancer 59, 823-829. 
 
 
92 
 
 
Section V: Curriculum Vitae 
93 
 
 
Marie-Aude BOUCABEILLE 
Niederlenzer Kirchweg 9 
5600 Lenzburg 
079 236 90 02 & 062 892 46 90 
 
 
maboucabeille@access.unizh.ch 
Date of birth: 10.07.1979 
Nationality : French 
 
EDUCATION 
2003-07  PhD student at the University of Zürich since October 03 
2002  Master : diploma of Biotechnology Engineer from the ‘Ecole Supérieure de 
Technologie des Biomolécules de Bordeaux (ESTBB)’, University 
Bordeaux 2, France 
1997-99  Preparation for admission to engineering schools : ‘Classes 
préparatoires’(Mathematics and Biology), Lycee J.Rostand, Strasbourg, 
France 
1997  Scientific Baccalauréat with honours, Colmar, France 
 
RESEARCH PROJECTS 
At this date 
(4 years) 
 PhD at the University of Zürich 
• Role of leukocytes during hematogenous metastasis 
2002 
(1 year) 
 Work at the ‘Université Libre de Bruxelles’ (Brussels, Belgium) on a 
cancer research project 
• Involvement of the S100A6 protein in glioma cell lines migration 
2001 
(6 months) 
 Diploma at the Laboratory of Clinical and Experimental Immunology at 
Transgene S.A (Strasbourg, France)  
• Project in Cancer Gene Therapy: ‘Evaluation of the effect of genes 
expressed in tumor cells on the human dendritic cells’ maturation’ 
2000 
(6 weeks) 
 Training in a R&D biochemistry laboratory at Novartis Crop Protection 
(Basel, Switzerland) 
• Extraction, purification and preliminary biochemical characterizations 
of a target protein 
   
FOREIGN LANGUAGES 
French  mother tongue 
German   written and fluently spoken 
English  written and fluently spoken 
 
 
LEISURE ACTIVITIES AND PERSONAL INTERESTS
1996-2001  Coaching groups of young scouts and teenagers at many outdoor centres 
and children’s holiday camps  
Permanent  Music (cello player) and hiking 
 
